<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="doi: 10.3390/ijms21103732ijms-21-03732 : Review Liquid Biopsy for the Diagnosis of" exact="Viral" post="Hepatitis, Fatty Liver Steatosis, and Alcoholic Liver Diseases ShabanguCiniso"/>
 <result pre="for the Diagnosis of Viral Hepatitis, Fatty Liver Steatosis, and" exact="Alcoholic" post="Liver Diseases ShabanguCiniso Sylvester12†https://orcid.org/0000-0002-2752-7051HuangJee-Fu2345†https://orcid.org/0000-0002-7381-1045HsiaoHui-Hua3YuMing-Lung23456ChuangWan-Long45https://orcid.org/0000-0001-9691-7507WangShu-Chi123*[1], u107567006@kmu.edu.tw[2], jf71218@gmail.comfish6069@gmail.com[3], huhuhs@cc.kmu.edu.tw[4], waloch@kmu.edu.tw[5], [6],"/>
 <result pre="the Diagnosis of Viral Hepatitis, Fatty Liver Steatosis, and Alcoholic" exact="Liver Diseases" post="ShabanguCiniso Sylvester12†https://orcid.org/0000-0002-2752-7051HuangJee-Fu2345†https://orcid.org/0000-0002-7381-1045HsiaoHui-Hua3YuMing-Lung23456ChuangWan-Long45https://orcid.org/0000-0001-9691-7507WangShu-Chi123*[1], u107567006@kmu.edu.tw[2], jf71218@gmail.comfish6069@gmail.com[3], huhuhs@cc.kmu.edu.tw[4], waloch@kmu.edu.tw[5], [6], *Correspondence: shuchiwang@kmu.edu.tw"/>
 <result pre="Diagnosis of Viral Hepatitis, Fatty Liver Steatosis, and Alcoholic Liver" exact="Diseases" post="ShabanguCiniso Sylvester12†https://orcid.org/0000-0002-2752-7051HuangJee-Fu2345†https://orcid.org/0000-0002-7381-1045HsiaoHui-Hua3YuMing-Lung23456ChuangWan-Long45https://orcid.org/0000-0001-9691-7507WangShu-Chi123*[1], u107567006@kmu.edu.tw[2], jf71218@gmail.comfish6069@gmail.com[3], huhuhs@cc.kmu.edu.tw[4], waloch@kmu.edu.tw[5], [6], *Correspondence: shuchiwang@kmu.edu.tw"/>
 <result pre="Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract During the progression from" exact="hepatitis" post="to fibrosis, cirrhosis, and liver failure, the accumulation of"/>
 <result pre="Abstract During the progression from hepatitis to fibrosis, cirrhosis, and" exact="liver failure," post="the accumulation of stressed/damaged hepatocyte elements associated with liver"/>
 <result pre="liver failure, the accumulation of stressed/damaged hepatocyte elements associated with" exact="liver inflammation" post="is critical. The causes of hepatocyte injuries include viral"/>
 <result pre="liver inflammation is critical. The causes of hepatocyte injuries include" exact="viral hepatitis" post="infections, alcoholic hepatitis, and non-alcoholic fatty liver disease. Hepatocyte-derived"/>
 <result pre="inflammation is critical. The causes of hepatocyte injuries include viral" exact="hepatitis" post="infections, alcoholic hepatitis, and non-alcoholic fatty liver disease. Hepatocyte-derived"/>
 <result pre="critical. The causes of hepatocyte injuries include viral hepatitis infections," exact="alcoholic hepatitis," post="and non-alcoholic fatty liver disease. Hepatocyte-derived extracellular vesicles (Hep-EVs)"/>
 <result pre="of hepatocyte injuries include viral hepatitis infections, alcoholic hepatitis, and" exact="non-alcoholic fatty liver" post="disease. Hepatocyte-derived extracellular vesicles (Hep-EVs) released from stressed/damaged hepatocytes"/>
 <result pre="hepatocyte injuries include viral hepatitis infections, alcoholic hepatitis, and non-alcoholic" exact="fatty liver disease." post="Hepatocyte-derived extracellular vesicles (Hep-EVs) released from stressed/damaged hepatocytes are"/>
 <result pre="injuries include viral hepatitis infections, alcoholic hepatitis, and non-alcoholic fatty" exact="liver disease." post="Hepatocyte-derived extracellular vesicles (Hep-EVs) released from stressed/damaged hepatocytes are"/>
 <result pre="vesicles (Hep-EVs) released from stressed/damaged hepatocytes are partly responsible for" exact="liver disease" post="progression and liver damage because they activate non-parenchymal cells"/>
 <result pre="(Hep-EVs) released from stressed/damaged hepatocytes are partly responsible for liver" exact="disease" post="progression and liver damage because they activate non-parenchymal cells"/>
 <result pre="placed on liquid biopsy methods for the long-term monitoring of" exact="chronic" post="liver diseases. In the present review, we have highlighted"/>
 <result pre="have highlighted various aspects of current liquid biopsy research into" exact="chronic" post="liver diseases. We have also reviewed recent progress on"/>
 <result pre="potential diagnostic tools and novel therapeutic targets in patients with" exact="viral hepatitis," post="fatty liver steatosis, and alcoholic liver diseases. viral hepatitis"/>
 <result pre="tools and novel therapeutic targets in patients with viral hepatitis," exact="fatty liver" post="steatosis, and alcoholic liver diseases. viral hepatitis non-alcoholic fatty"/>
 <result pre="and novel therapeutic targets in patients with viral hepatitis, fatty" exact="liver steatosis," post="and alcoholic liver diseases. viral hepatitis non-alcoholic fatty liver"/>
 <result pre="targets in patients with viral hepatitis, fatty liver steatosis, and" exact="alcoholic" post="liver diseases. viral hepatitis non-alcoholic fatty liver disease alcoholic"/>
 <result pre="with viral hepatitis, fatty liver steatosis, and alcoholic liver diseases." exact="viral hepatitis" post="non-alcoholic fatty liver disease alcoholic liver disease biomarkers extracellular"/>
 <result pre="viral hepatitis, fatty liver steatosis, and alcoholic liver diseases. viral" exact="hepatitis" post="non-alcoholic fatty liver disease alcoholic liver disease biomarkers extracellular"/>
 <result pre="hepatitis, fatty liver steatosis, and alcoholic liver diseases. viral hepatitis" exact="non-alcoholic fatty liver" post="disease alcoholic liver disease biomarkers extracellular vesicles microparticles exosomes"/>
 <result pre="fatty liver steatosis, and alcoholic liver diseases. viral hepatitis non-alcoholic" exact="fatty liver disease" post="alcoholic liver disease biomarkers extracellular vesicles microparticles exosomes 1."/>
 <result pre="liver steatosis, and alcoholic liver diseases. viral hepatitis non-alcoholic fatty" exact="liver disease" post="alcoholic liver disease biomarkers extracellular vesicles microparticles exosomes 1."/>
 <result pre="steatosis, and alcoholic liver diseases. viral hepatitis non-alcoholic fatty liver" exact="disease" post="alcoholic liver disease biomarkers extracellular vesicles microparticles exosomes 1."/>
 <result pre="and alcoholic liver diseases. viral hepatitis non-alcoholic fatty liver disease" exact="alcoholic" post="liver disease biomarkers extracellular vesicles microparticles exosomes 1. Introduction"/>
 <result pre="alcoholic liver diseases. viral hepatitis non-alcoholic fatty liver disease alcoholic" exact="liver disease" post="biomarkers extracellular vesicles microparticles exosomes 1. Introduction Chronic liver"/>
 <result pre="liver diseases. viral hepatitis non-alcoholic fatty liver disease alcoholic liver" exact="disease" post="biomarkers extracellular vesicles microparticles exosomes 1. Introduction Chronic liver"/>
 <result pre="alcoholic liver disease biomarkers extracellular vesicles microparticles exosomes 1. Introduction" exact="Chronic" post="liver disease is a major public health issue globally."/>
 <result pre="liver disease biomarkers extracellular vesicles microparticles exosomes 1. Introduction Chronic" exact="liver disease" post="is a major public health issue globally. It includes"/>
 <result pre="disease biomarkers extracellular vesicles microparticles exosomes 1. Introduction Chronic liver" exact="disease" post="is a major public health issue globally. It includes"/>
 <result pre="disease is a major public health issue globally. It includes" exact="chronic" post="viral hepatitis, fatty liver disease, among other causes, and"/>
 <result pre="is a major public health issue globally. It includes chronic" exact="viral hepatitis," post="fatty liver disease, among other causes, and accounts for"/>
 <result pre="major public health issue globally. It includes chronic viral hepatitis," exact="fatty liver disease," post="among other causes, and accounts for approximately 3.5% of"/>
 <result pre="public health issue globally. It includes chronic viral hepatitis, fatty" exact="liver disease," post="among other causes, and accounts for approximately 3.5% of"/>
 <result pre="other causes, and accounts for approximately 3.5% of deaths [1]." exact="Viral hepatitis" post="is a persistent state of liver inflammation caused by"/>
 <result pre="causes, and accounts for approximately 3.5% of deaths [1]. Viral" exact="hepatitis" post="is a persistent state of liver inflammation caused by"/>
 <result pre="3.5% of deaths [1]. Viral hepatitis is a persistent state" exact="of liver" post="inflammation caused by various viruses. It increases the risk"/>
 <result pre="of deaths [1]. Viral hepatitis is a persistent state of" exact="liver inflammation" post="caused by various viruses. It increases the risk of"/>
 <result pre="inflammation caused by various viruses. It increases the risk of" exact="cirrhosis" post="and hepatocellular carcinoma (HCC). Chronic hepatitis B virus (CHB)"/>
 <result pre="by various viruses. It increases the risk of cirrhosis and" exact="hepatocellular carcinoma" post="(HCC). Chronic hepatitis B virus (CHB) and chronic hepatitis"/>
 <result pre="various viruses. It increases the risk of cirrhosis and hepatocellular" exact="carcinoma" post="(HCC). Chronic hepatitis B virus (CHB) and chronic hepatitis"/>
 <result pre="It increases the risk of cirrhosis and hepatocellular carcinoma (HCC)." exact="Chronic" post="hepatitis B virus (CHB) and chronic hepatitis C virus"/>
 <result pre="increases the risk of cirrhosis and hepatocellular carcinoma (HCC). Chronic" exact="hepatitis" post="B virus (CHB) and chronic hepatitis C virus (CHC)"/>
 <result pre="and hepatocellular carcinoma (HCC). Chronic hepatitis B virus (CHB) and" exact="chronic hepatitis" post="C virus (CHC) infections are major risk factors for"/>
 <result pre="hepatocellular carcinoma (HCC). Chronic hepatitis B virus (CHB) and chronic" exact="hepatitis" post="C virus (CHC) infections are major risk factors for"/>
 <result pre="hepatitis B virus (CHB) and chronic hepatitis C virus (CHC)" exact="infections" post="are major risk factors for HCC, and the association"/>
 <result pre="45 to 80% in various regional epidemics. In recent decades," exact="non-alcoholic fatty liver" post="disease (NAFLD) and alcohol-associated liver disease have emerged as"/>
 <result pre="to 80% in various regional epidemics. In recent decades, non-alcoholic" exact="fatty liver disease" post="(NAFLD) and alcohol-associated liver disease have emerged as urgent"/>
 <result pre="80% in various regional epidemics. In recent decades, non-alcoholic fatty" exact="liver disease" post="(NAFLD) and alcohol-associated liver disease have emerged as urgent"/>
 <result pre="in various regional epidemics. In recent decades, non-alcoholic fatty liver" exact="disease" post="(NAFLD) and alcohol-associated liver disease have emerged as urgent"/>
 <result pre="In recent decades, non-alcoholic fatty liver disease (NAFLD) and alcohol-associated" exact="liver disease" post="have emerged as urgent etiologies associated with an increasingly"/>
 <result pre="recent decades, non-alcoholic fatty liver disease (NAFLD) and alcohol-associated liver" exact="disease" post="have emerged as urgent etiologies associated with an increasingly"/>
 <result pre="noting that the increase in non-alcoholic steatohepatitis (NASH) associated with" exact="obesity" post="and metabolic syndrome may have led, directly or indirectly,"/>
 <result pre="the increase in non-alcoholic steatohepatitis (NASH) associated with obesity and" exact="metabolic syndrome" post="may have led, directly or indirectly, to an increase"/>
 <result pre="increase in non-alcoholic steatohepatitis (NASH) associated with obesity and metabolic" exact="syndrome" post="may have led, directly or indirectly, to an increase"/>
 <result pre="advanced HCC stage and poor overall survival [3,4]. Because most" exact="NAFLD" post="patients are asymptomatic, a feasible follow-up schedule and an"/>
 <result pre="elusive owing to the potential risk of cirrhosis, HCC, and" exact="liver failure" post="in certain patients [5]. Liver biopsy remains the gold"/>
 <result pre="biopsy remains the gold standard for the diagnosis of various" exact="chronic" post="liver diseases, and for determining the patterns and severity"/>
 <result pre="chronic liver diseases, and for determining the patterns and severity" exact="of liver" post="injury, inflammation, and fibrosis stage. However, liver biopsy is"/>
 <result pre="are not sufficiently sensitive or specific and are therefore of" exact="limited" post="use. Various imaging modalities—including magnetic resonance imaging (MRI)-based and"/>
 <result pre="resonance imaging (MRI)-based and ultrasound-based elastography—are used for the assessment" exact="of liver" post="steatosis and fibrosis, but there is much room for"/>
 <result pre="imaging (MRI)-based and ultrasound-based elastography—are used for the assessment of" exact="liver steatosis" post="and fibrosis, but there is much room for improvement"/>
 <result pre="might provide significant advances in the diagnosis and monitoring of" exact="disease" post="progression and regression in clinical settings. Liquid biopsy has"/>
 <result pre="and long non-coding RNA (lncRNA) are potential tools for monitoring" exact="tumor" post="dynamics in terms of the early detection of de"/>
 <result pre="are implicated in various pathways, including those involving detoxification, endosomes," exact="cytosolic" post="proteins, apolipoproteins, and coagulation-associated proteins. MPs/MVs have been found"/>
 <result pre="of hepatocyte-derived exosomes [13]. EVs are formed by various types" exact="of liver" post="cells, such as hepatocytes, hepatic stellate cells (HSCs), endothelial"/>
 <result pre="EVs are expelled into the extracellular space by various types" exact="of liver" post="cells and are thereby introduced into the circulation. Long"/>
 <result pre="(cccDNA) and pre-genomic RNA (pgRNA) formed during the replication of" exact="hepatitis" post="B virus (HBV). The assembly of proteins and nucleic"/>
 <result pre="derived from cells or organs under stress or affected by" exact="disease" post="are potential biomarkers as they are different from those"/>
 <result pre="methods are now used widely to detect many aspects of" exact="chronic" post="liver diseases. They are informative and provide in-depth information"/>
 <result pre="informative and provide in-depth information about the diverse spectrum of" exact="disease" post="progression. 2. Liquid Biopsies for Viral Hepatitis 2.1. Liquid"/>
 <result pre="the diverse spectrum of disease progression. 2. Liquid Biopsies for" exact="Viral" post="Hepatitis 2.1. Liquid Biopsies Associated Viral Hepatitis Infections Viral"/>
 <result pre="diverse spectrum of disease progression. 2. Liquid Biopsies for Viral" exact="Hepatitis" post="2.1. Liquid Biopsies Associated Viral Hepatitis Infections Viral hepatitis"/>
 <result pre="2. Liquid Biopsies for Viral Hepatitis 2.1. Liquid Biopsies Associated" exact="Viral" post="Hepatitis Infections Viral hepatitis is an inflammation of the"/>
 <result pre="Liquid Biopsies for Viral Hepatitis 2.1. Liquid Biopsies Associated Viral" exact="Hepatitis" post="Infections Viral hepatitis is an inflammation of the liver"/>
 <result pre="Biopsies for Viral Hepatitis 2.1. Liquid Biopsies Associated Viral Hepatitis" exact="Infections" post="Viral hepatitis is an inflammation of the liver associated"/>
 <result pre="for Viral Hepatitis 2.1. Liquid Biopsies Associated Viral Hepatitis Infections" exact="Viral hepatitis" post="is an inflammation of the liver associated with infection"/>
 <result pre="Viral Hepatitis 2.1. Liquid Biopsies Associated Viral Hepatitis Infections Viral" exact="hepatitis" post="is an inflammation of the liver associated with infection"/>
 <result pre="Viral hepatitis is an inflammation of the liver associated with" exact="infection" post="by a hepatitis virus. Researchers have debated whether viruses"/>
 <result pre="an inflammation of the liver associated with infection by a" exact="hepatitis" post="virus. Researchers have debated whether viruses have infection strategies"/>
 <result pre="by a hepatitis virus. Researchers have debated whether viruses have" exact="infection" post="strategies that integrate EV-regulated communication pathways [15]. For example,"/>
 <result pre="the surfaces of exosomes in numerous studies. This suggests that" exact="hepatitis" post="viruses may incorporate themselves into EVs during biogenesis to"/>
 <result pre="viruses may incorporate themselves into EVs during biogenesis to enhance" exact="viral" post="spread, as indicted by cell models and serum samples"/>
 <result pre="spread, as indicted by cell models and serum samples [18,19,20]." exact="Hepatitis" post="A—which is a picornavirus—uses the host’s EV machinery to"/>
 <result pre="is a picornavirus—uses the host’s EV machinery to propagate enveloped" exact="hepatitis" post="A (eHAV); it comprises of two components: a nonenveloped"/>
 <result pre="and eventually enter the blood [22]. This indicates that encapsulated" exact="viral" post="vesicles, like exosomes, are protected from antibody-mediated neutralization [21]."/>
 <result pre="are transported and delivered by MVBs. Simultaneously, machinery perturbation arrests" exact="viral" post="maturation by blocking the encapsulation of viral envelope proteins"/>
 <result pre="machinery perturbation arrests viral maturation by blocking the encapsulation of" exact="viral" post="envelope proteins derived from solvent-insoluble membranes. This may hinder"/>
 <result pre="viral envelope proteins derived from solvent-insoluble membranes. This may hinder" exact="viral" post="propagation. As with EVs, hepatitis C virus (HCV) targets"/>
 <result pre="solvent-insoluble membranes. This may hinder viral propagation. As with EVs," exact="hepatitis" post="C virus (HCV) targets are determined by multiple factors."/>
 <result pre="virus (HCV) targets are determined by multiple factors. The HCV" exact="viral" post="entry mechanism has evolved considerably and requires numerous molecules"/>
 <result pre="Differentiation 81 (CD81), Claudin 1 (CLDN-1), Scavenger receptor class B" exact="type 1" post="(SR-B1), and Occludin (OCLN), which illustrates the intricacy of"/>
 <result pre="vivo studies have also confirmed that anti-CD81 antibodies can suppress" exact="viral infection" post="[26,27]. Moreover, EVs isolated from the sera of CHC"/>
 <result pre="studies have also confirmed that anti-CD81 antibodies can suppress viral" exact="infection" post="[26,27]. Moreover, EVs isolated from the sera of CHC"/>
 <result pre="only contain HCV RNA and independently regulate HCV replication via" exact="viral" post="receptors, but are also corelated with HSP90, Argonaute RISC"/>
 <result pre="naive cells [25]. GB virus C (GBV-C), formally known as" exact="hepatitis" post="G virus (HGV), is a member of the Flaviviridae"/>
 <result pre="suggest that EVs play various functions in the pathogenesis of" exact="viral hepatitis" post="as shown in Figure 1. 2.2. Liquid Biopsies Associated"/>
 <result pre="that EVs play various functions in the pathogenesis of viral" exact="hepatitis" post="as shown in Figure 1. 2.2. Liquid Biopsies Associated"/>
 <result pre="hepatitis as shown in Figure 1. 2.2. Liquid Biopsies Associated" exact="Viral" post="Hepatitis Immunity EVs also allow HCV to evade immunity"/>
 <result pre="as shown in Figure 1. 2.2. Liquid Biopsies Associated Viral" exact="Hepatitis" post="Immunity EVs also allow HCV to evade immunity by"/>
 <result pre="evade immunity by protecting the HCV RNA from degradation. The" exact="hepatitis" post="A virus evades the human immune response by becoming"/>
 <result pre="the differentiation of monocytes into macrophages and hepatic macrophage recruitment." exact="Elevated" post="numbers of platelet-derived EVs are also associated with liver"/>
 <result pre="recruitment. Elevated numbers of platelet-derived EVs are also associated with" exact="liver fibrosis" post="biomarkers, such as serum hyaluronate and the N-terminal propeptide"/>
 <result pre="biomarkers, such as serum hyaluronate and the N-terminal propeptide of" exact="type III" post="procollagen [31]. Patients with chronic HCV infection experience greater"/>
 <result pre="the N-terminal propeptide of type III procollagen [31]. Patients with" exact="chronic" post="HCV infection experience greater platelet activation and increased levels"/>
 <result pre="propeptide of type III procollagen [31]. Patients with chronic HCV" exact="infection" post="experience greater platelet activation and increased levels of circulating"/>
 <result pre="increased levels of circulating platelet-derived EVs compared to those with" exact="chronic" post="HBV infection. Immune cell-derived circulating EVs are associated with"/>
 <result pre="HBV infection. Immune cell-derived circulating EVs are associated with advanced" exact="liver disease" post="and may be identified by microparticle markers of cell"/>
 <result pre="infection. Immune cell-derived circulating EVs are associated with advanced liver" exact="disease" post="and may be identified by microparticle markers of cell"/>
 <result pre="cells by Valpha24/Vbeta11 [32]. CHC patients can be identified among" exact="chronic hepatitis" post="patients by cell-derived EV biomarkers. The authors of another"/>
 <result pre="by Valpha24/Vbeta11 [32]. CHC patients can be identified among chronic" exact="hepatitis" post="patients by cell-derived EV biomarkers. The authors of another"/>
 <result pre="infected liver cells [33]. The immune cells are implicated in" exact="liver inflammation" post="and liver-related diseases by host immune system regulation and"/>
 <result pre="of the microenvironment [34]. 2.3. Biomarkers of Liquid Biopsies Associated" exact="Viral" post="Hepatitis Nucleic acids and viral hepatitis-associated proteins have been"/>
 <result pre="the microenvironment [34]. 2.3. Biomarkers of Liquid Biopsies Associated Viral" exact="Hepatitis" post="Nucleic acids and viral hepatitis-associated proteins have been identified"/>
 <result pre="Biomarkers of Liquid Biopsies Associated Viral Hepatitis Nucleic acids and" exact="viral" post="hepatitis-associated proteins have been identified in EVs from the"/>
 <result pre="been identified in EVs from the sera of patients with" exact="chronic" post="viral infections [35]. Long non-coding RNAs (lncRNAs) can affect"/>
 <result pre="identified in EVs from the sera of patients with chronic" exact="viral" post="infections [35]. Long non-coding RNAs (lncRNAs) can affect the"/>
 <result pre="in EVs from the sera of patients with chronic viral" exact="infections" post="[35]. Long non-coding RNAs (lncRNAs) can affect the regulation"/>
 <result pre="higher levels of exosomal HNRNPH1 in HBV-associated HCC patients with" exact="vascular" post="invasion and lymph node metastasis than those in non-HCC"/>
 <result pre="exosomal HNRNPH1 in HBV-associated HCC patients with vascular invasion and" exact="lymph node metastasis" post="than those in non-HCC patients [36]. A positive correlation"/>
 <result pre="in HBV-associated HCC patients with vascular invasion and lymph node" exact="metastasis" post="than those in non-HCC patients [36]. A positive correlation"/>
 <result pre="non-HCC patients [36]. A positive correlation among lncRNA-HULC, lncRNA-HEIH, and" exact="hepatitis" post="B X-interacting protein (HBXIP) indicated that hepatitis B X"/>
 <result pre="lncRNA-HULC, lncRNA-HEIH, and hepatitis B X-interacting protein (HBXIP) indicated that" exact="hepatitis" post="B X protein (HBx) may alter lncRNA expression, which"/>
 <result pre="HCV-related HCC patients, whereas serum lncRNA-HEIH expression levels are significantly" exact="lower" post="than exosomal lncRNA-HEIH expression levels in CHC patients [39]."/>
 <result pre="(SNP) rs2596538 [40]. There was an increase in the risk" exact="of liver" post="fibrosis in the CHC patients with the G allele,"/>
 <result pre="rs2596538 [40]. There was an increase in the risk of" exact="liver fibrosis" post="in the CHC patients with the G allele, whereas"/>
 <result pre="of sMICA were elevated in the HCV-associated HCC patients following" exact="viral" post="eradication [41,42]. A genome-wide association study (GWAS) demonstrated that"/>
 <result pre="viral eradication [41,42]. A genome-wide association study (GWAS) demonstrated that" exact="elevated serum" post="levels of MICA and soluble MICA (sMICA)—encoded by the"/>
 <result pre="resulting from SNP rs2596542—increased the risk of HBV-associated HCC [43]." exact="Viral" post="amplification and replication could be used in target detection."/>
 <result pre="Viral amplification and replication could be used in target detection." exact="Chronic" post="HBV infection is characterized by a persistent episomal viral"/>
 <result pre="and replication could be used in target detection. Chronic HBV" exact="infection" post="is characterized by a persistent episomal viral genome, namely"/>
 <result pre="detection. Chronic HBV infection is characterized by a persistent episomal" exact="viral" post="genome, namely covalently closed circular DNA (cccDNA). cccDNA constitutes"/>
 <result pre="genome, namely covalently closed circular DNA (cccDNA). cccDNA constitutes a" exact="stable" post="mini-chromosome within the infected hepatocyte nucleus [44]. The persistence"/>
 <result pre="system to eradicate the virus contribute to the failure of" exact="viral" post="clearance and to relapse, even after treatment goals have"/>
 <result pre="HBV clearance or functional cure is generally defined as the" exact="complete" post="elimination of cccDNA from infected hepatocytes [44]. Theoretically, even"/>
 <result pre="therapy. The presence of pre-genomic RNA (pgRNA) in mature HBV" exact="viral" post="particle nucleocapsids is linked to the persistence of viral"/>
 <result pre="HBV viral particle nucleocapsids is linked to the persistence of" exact="viral infection" post="and the risk of virological recurrence. Lin et al."/>
 <result pre="viral particle nucleocapsids is linked to the persistence of viral" exact="infection" post="and the risk of virological recurrence. Lin et al."/>
 <result pre="to make a better assessment of changes in the sustained" exact="viral" post="response (SVR) [45]. Regarding pathogenic cell-free genomics, Tokuhisa et"/>
 <result pre="between the level of cfDNA in the serum and the" exact="metastatic" post="capability of HCV-related HCC, which suggests the potential of"/>
 <result pre="HCC, which suggests the potential of cfDNA as an active" exact="metastasis" post="biomarker following curative surgery [47]. Patients with CHC-related HCC"/>
 <result pre="is 20 times higher than in healthy controls [48]. The" exact="viral" post="hepatitis-related liquid biomarkers are listed in Table 1. 3."/>
 <result pre="listed in Table 1. 3. Liquid Biopsies for the Fatty" exact="Liver Disease" post="3.1. Biomarkers Associated Non-Alcoholic Steatohepatitis/Non-Alcoholic Fatty Liver Disease (NASH/NAFLD)"/>
 <result pre="in Table 1. 3. Liquid Biopsies for the Fatty Liver" exact="Disease" post="3.1. Biomarkers Associated Non-Alcoholic Steatohepatitis/Non-Alcoholic Fatty Liver Disease (NASH/NAFLD)"/>
 <result pre="the Fatty Liver Disease 3.1. Biomarkers Associated Non-Alcoholic Steatohepatitis/Non-Alcoholic Fatty" exact="Liver Disease" post="(NASH/NAFLD) NAFLD is a well-known liver disorder, with 25%"/>
 <result pre="Fatty Liver Disease 3.1. Biomarkers Associated Non-Alcoholic Steatohepatitis/Non-Alcoholic Fatty Liver" exact="Disease" post="(NASH/NAFLD) NAFLD is a well-known liver disorder, with 25%"/>
 <result pre="Disease 3.1. Biomarkers Associated Non-Alcoholic Steatohepatitis/Non-Alcoholic Fatty Liver Disease (NASH/NAFLD)" exact="NAFLD" post="is a well-known liver disorder, with 25% prevalence across"/>
 <result pre="Non-Alcoholic Steatohepatitis/Non-Alcoholic Fatty Liver Disease (NASH/NAFLD) NAFLD is a well-known" exact="liver disorder," post="with 25% prevalence across the globe. It is broadly"/>
 <result pre="is the severe form of NAFLD, which is characterized by" exact="lobular" post="inflammation or the chronic low-grade proinflammatory state of hepatocytes"/>
 <result pre="of NAFLD, which is characterized by lobular inflammation or the" exact="chronic" post="low-grade proinflammatory state of hepatocytes with or without fibrosis."/>
 <result pre="chronic low-grade proinflammatory state of hepatocytes with or without fibrosis." exact="NAFLD" post="is currently the most prevalent cause of liver transplantation"/>
 <result pre="or without fibrosis. NAFLD is currently the most prevalent cause" exact="of liver" post="transplantation [49]. The prevalence of NAFLD has increased rapidly"/>
 <result pre="most prevalent cause of liver transplantation [49]. The prevalence of" exact="NAFLD" post="has increased rapidly over the past few decades in"/>
 <result pre="in the Asia–Pacific region, at a comparable rate to westernization." exact="NAFLD" post="is an intermediate stage in various progressive diseases that"/>
 <result pre="region, at a comparable rate to westernization. NAFLD is an" exact="intermediate" post="stage in various progressive diseases that are not associated"/>
 <result pre="fibrosis, cirrhosis, and HCC. Lipotoxicity develops during the progression of" exact="NAFLD" post="owing to the accumulation of toxic lipids and stressed/damaged"/>
 <result pre="stressed/damaged hepatocytes; it is linked to metabolic disorders including dyslipidemia," exact="type 2" post="diabetes, and obesity [50]. Various mechanisms contribute to the"/>
 <result pre="is linked to metabolic disorders including dyslipidemia, type 2 diabetes," exact="and obesity" post="[50]. Various mechanisms contribute to the intrahepatic accumulation of"/>
 <result pre="linked to metabolic disorders including dyslipidemia, type 2 diabetes, and" exact="obesity" post="[50]. Various mechanisms contribute to the intrahepatic accumulation of"/>
 <result pre="(TAGs), and a positive hepatic histological index distinguishes NASH in" exact="NAFLD" post="patients [52]. Minimal TAG levels may be hepato-protective, whereas"/>
 <result pre="index and may be used as a severity predictor in" exact="NAFLD" post="diagnoses [55]. The authors of another study found that"/>
 <result pre="found that homocysteine (Hcy) serum concentrations are significantly higher in" exact="NAFLD" post="patients and are not influenced by chronic hepatitis [56]."/>
 <result pre="significantly higher in NAFLD patients and are not influenced by" exact="chronic hepatitis" post="[56]. Furthermore, there is a positive correlation between plasma"/>
 <result pre="higher in NAFLD patients and are not influenced by chronic" exact="hepatitis" post="[56]. Furthermore, there is a positive correlation between plasma"/>
 <result pre="as glutathione (GSH) were demonstrated to be decreases in the" exact="NAFLD" post="patients compared to healthy individuals [58]. Proline and hydroxyproline,"/>
 <result pre="also observed to be elevated in serum of patients with" exact="NAFLD" post="compared to healthy individuals [59]. Another study indicated that"/>
 <result pre="that a rate-limiting enzyme Acetyl-CoA carboxylase (ACC) increased expression in" exact="NAFLD" post="animal models [60]. Indeed, Alkaline phosphatase (ALKP) elevated levels"/>
 <result pre="[60]. Indeed, Alkaline phosphatase (ALKP) elevated levels are associated with" exact="hepatic fibrosis" post="in steatohepatitis patients. ALKP serum level are notably higher"/>
 <result pre="without NASH [61]. 3.2. Hepatocyte-Derived Vesicles Associated Non-Alcoholic Steatohepatitis/Non-Alcoholic Fatty" exact="Liver Disease" post="(NASH/NAFLD) With regards to NAFLD, EVs play a key"/>
 <result pre="NASH [61]. 3.2. Hepatocyte-Derived Vesicles Associated Non-Alcoholic Steatohepatitis/Non-Alcoholic Fatty Liver" exact="Disease" post="(NASH/NAFLD) With regards to NAFLD, EVs play a key"/>
 <result pre="to NAFLD, EVs play a key role in the mechanism" exact="of liver" post="damage and disease progression through the accumulation of lipotoxic"/>
 <result pre="a key role in the mechanism of liver damage and" exact="disease" post="progression through the accumulation of lipotoxic lipids in hepatocytes."/>
 <result pre="are discharged from damaged or stressed hepatic cells—exacerbate the progression" exact="of liver" post="disease through the stimulation of non-parenchymal cells [62]. In"/>
 <result pre="discharged from damaged or stressed hepatic cells—exacerbate the progression of" exact="liver disease" post="through the stimulation of non-parenchymal cells [62]. In mouse"/>
 <result pre="from damaged or stressed hepatic cells—exacerbate the progression of liver" exact="disease" post="through the stimulation of non-parenchymal cells [62]. In mouse"/>
 <result pre="of non-parenchymal cells [62]. In mouse hepatocytes and human hepatocyte-derived" exact="carcinoma" post="cell (HuH) models, palmitate and lysophosphatidylcholine (LPC) increase the"/>
 <result pre="to NASH, lipids facilitate the release of EVs through the" exact="tumor" post="necrosis factor receptor superfamily member 10B (TNFRSF10B) signaling pathway"/>
 <result pre="[66]. 3.3. Liquid Biopsies Associated Chemoattraction in Non-Alcoholic Steatohepatitis/Non-Alcoholic Fatty" exact="Liver Disease" post="(NASH/NAFLD) EVs play a role in cell-to-cell communication by"/>
 <result pre="3.3. Liquid Biopsies Associated Chemoattraction in Non-Alcoholic Steatohepatitis/Non-Alcoholic Fatty Liver" exact="Disease" post="(NASH/NAFLD) EVs play a role in cell-to-cell communication by"/>
 <result pre="into target cells while regulating NASH pathogenesis and progression. The" exact="fatty liver" post="disease-related liquid biomarkers are listed in Table 2. Macrophage"/>
 <result pre="influx in the liver are important for the progression of" exact="NAFLD" post="because hepatic macrophages promote NASH development via cytokines IL-1,"/>
 <result pre="EVs derived from hepatocytes containing excessive levels of lipids promote" exact="liver fibrosis" post="through pro-inflammation, which directly affects immune cells. Kornek et"/>
 <result pre="monocytes—which are associated with alanine transaminase (ALT)—in plasma samples from" exact="NAFLD" post="patients [32]. There is an increase in inflammatory cell-derived"/>
 <result pre="[32]. There is an increase in inflammatory cell-derived Hep-EVs in" exact="NAFLD" post="patients and in patients with either or both of"/>
 <result pre="patients and in patients with either or both of alcohol-related" exact="cirrhosis" post="and chronic hepatitis C-related cirrhosis [32,71]. Immature myeloid cells"/>
 <result pre="in patients with either or both of alcohol-related cirrhosis and" exact="chronic hepatitis" post="C-related cirrhosis [32,71]. Immature myeloid cells (CD11b+, Ly6Chi, Ly6G-)"/>
 <result pre="patients with either or both of alcohol-related cirrhosis and chronic" exact="hepatitis" post="C-related cirrhosis [32,71]. Immature myeloid cells (CD11b+, Ly6Chi, Ly6G-)"/>
 <result pre="either or both of alcohol-related cirrhosis and chronic hepatitis C-related" exact="cirrhosis" post="[32,71]. Immature myeloid cells (CD11b+, Ly6Chi, Ly6G-) have also"/>
 <result pre="[72]. Furthermore, mesenchymal stem cell (MSC)-derived EVs are linked to" exact="liver inflammation" post="and NASH progress, and are associated with increased proinflammatory"/>
 <result pre="with increased proinflammatory markers (TNF-α, IL-1β, IL-6, and IL-12) [73]." exact="Mouse" post="obesity models have been used to demonstrate that levels"/>
 <result pre="increased proinflammatory markers (TNF-α, IL-1β, IL-6, and IL-12) [73]. Mouse" exact="obesity" post="models have been used to demonstrate that levels of"/>
 <result pre="by the liquid biopsies and significantly associated with the progression" exact="of liver" post="fibrosis [76]. To date, the literature indicates that the"/>
 <result pre="the liquid biopsies and significantly associated with the progression of" exact="liver fibrosis" post="[76]. To date, the literature indicates that the EVs"/>
 <result pre="by lipid accumulation and their effects. 4. Liquid Biopsies for" exact="Alcoholic" post="Liver Disease (ALD) 4.1. Biomarkers Associated Alcoholic Liver Disease"/>
 <result pre="lipid accumulation and their effects. 4. Liquid Biopsies for Alcoholic" exact="Liver Disease" post="(ALD) 4.1. Biomarkers Associated Alcoholic Liver Disease (ALD) Alcoholic"/>
 <result pre="accumulation and their effects. 4. Liquid Biopsies for Alcoholic Liver" exact="Disease" post="(ALD) 4.1. Biomarkers Associated Alcoholic Liver Disease (ALD) Alcoholic"/>
 <result pre="Liquid Biopsies for Alcoholic Liver Disease (ALD) 4.1. Biomarkers Associated" exact="Alcoholic" post="Liver Disease (ALD) Alcoholic liver disease (ALD) foreshadows a"/>
 <result pre="Biopsies for Alcoholic Liver Disease (ALD) 4.1. Biomarkers Associated Alcoholic" exact="Liver Disease" post="(ALD) Alcoholic liver disease (ALD) foreshadows a wide variety"/>
 <result pre="for Alcoholic Liver Disease (ALD) 4.1. Biomarkers Associated Alcoholic Liver" exact="Disease" post="(ALD) Alcoholic liver disease (ALD) foreshadows a wide variety"/>
 <result pre="Liver Disease (ALD) 4.1. Biomarkers Associated Alcoholic Liver Disease (ALD)" exact="Alcoholic" post="liver disease (ALD) foreshadows a wide variety of liver"/>
 <result pre="Disease (ALD) 4.1. Biomarkers Associated Alcoholic Liver Disease (ALD) Alcoholic" exact="liver disease" post="(ALD) foreshadows a wide variety of liver pathologies from"/>
 <result pre="(ALD) 4.1. Biomarkers Associated Alcoholic Liver Disease (ALD) Alcoholic liver" exact="disease" post="(ALD) foreshadows a wide variety of liver pathologies from"/>
 <result pre="Disease (ALD) Alcoholic liver disease (ALD) foreshadows a wide variety" exact="of liver" post="pathologies from basic steatosis to advanced liver injuries such"/>
 <result pre="to advanced liver injuries such as steatohepatitis and fibrosis/cirrhosis [77]." exact="Steatosis" post="almost always occurs in the hepatocytes of people that"/>
 <result pre="steatohepatitis through neutrophil infiltration and related inflammation [78]. Excessive alcohol" exact="consumption" post="promotes the production of prooxidants and strengthens the antioxidant"/>
 <result pre="to hepatocyte injury accompanied by inflammation; this eventually results in" exact="liver failure" post="or cancer [79]. ALD hepatitis is directly related to"/>
 <result pre="accompanied by inflammation; this eventually results in liver failure or" exact="cancer" post="[79]. ALD hepatitis is directly related to the toxic"/>
 <result pre="this eventually results in liver failure or cancer [79]. ALD" exact="hepatitis" post="is directly related to the toxic effects of alcohol."/>
 <result pre="toxic effects of alcohol. It is indirectly caused by fecal" exact="infection" post="or adipose tissue impairment resulting from bacteria-related endotoxins, including"/>
 <result pre="reversible. Trinchet et al. (1994) reported that elevated levels of" exact="primary" post="bile acids are associated with alcoholic hepatitis (AH) [80]."/>
 <result pre="that elevated levels of primary bile acids are associated with" exact="alcoholic hepatitis" post="(AH) [80]. Moratti et al. reported that increased plasma"/>
 <result pre="elevated levels of primary bile acids are associated with alcoholic" exact="hepatitis" post="(AH) [80]. Moratti et al. reported that increased plasma"/>
 <result pre="gamma (PTPRG) isoform sPTPRG in EVs excreted from the human" exact="hepatocellular carcinoma" post="cell line HepG2 are associated with alcohol-related hepatic injury"/>
 <result pre="(PTPRG) isoform sPTPRG in EVs excreted from the human hepatocellular" exact="carcinoma" post="cell line HepG2 are associated with alcohol-related hepatic injury"/>
 <result pre="highly expressed in the hepatocytes of a mice model following" exact="chronic" post="and binge alcohol consumption, and in alcoholic hepatitis (AH)"/>
 <result pre="mice model following chronic and binge alcohol consumption, and in" exact="alcoholic hepatitis" post="(AH) patients [82]. The summary of the liquid factors"/>
 <result pre="model following chronic and binge alcohol consumption, and in alcoholic" exact="hepatitis" post="(AH) patients [82]. The summary of the liquid factors"/>
 <result pre="patients [82]. The summary of the liquid factors associated with" exact="liver inflammation" post="in ALD as shown in Figure 3 in advance."/>
 <result pre="shown in Figure 3 in advance. 4.2. Hepatocyte-Derived Vesicles Associated" exact="Alcoholic" post="Liver Disease (ALD) Investigations into EVs as biomarkers for"/>
 <result pre="in Figure 3 in advance. 4.2. Hepatocyte-Derived Vesicles Associated Alcoholic" exact="Liver Disease" post="(ALD) Investigations into EVs as biomarkers for alcoholic hepatitis"/>
 <result pre="Figure 3 in advance. 4.2. Hepatocyte-Derived Vesicles Associated Alcoholic Liver" exact="Disease" post="(ALD) Investigations into EVs as biomarkers for alcoholic hepatitis"/>
 <result pre="Alcoholic Liver Disease (ALD) Investigations into EVs as biomarkers for" exact="alcoholic hepatitis" post="in humans have revealed increased levels of EVs in"/>
 <result pre="Liver Disease (ALD) Investigations into EVs as biomarkers for alcoholic" exact="hepatitis" post="in humans have revealed increased levels of EVs in"/>
 <result pre="hepatitis in humans have revealed increased levels of EVs in" exact="alcoholic hepatitis" post="patients and patients who consume excessive amounts of alcohol"/>
 <result pre="in humans have revealed increased levels of EVs in alcoholic" exact="hepatitis" post="patients and patients who consume excessive amounts of alcohol"/>
 <result pre="in the circulation increase the likelihood of progression to advanced-stage" exact="disease" post="through fecal infection [85]. EV levels are elevated in"/>
 <result pre="increase the likelihood of progression to advanced-stage disease through fecal" exact="infection" post="[85]. EV levels are elevated in patients with a"/>
 <result pre="fragments M30 and M65 in EVs [90]. The severity of" exact="alcoholic hepatitis" post="is linked to EVs containing CD34+ and ASGPR+ [91]."/>
 <result pre="M30 and M65 in EVs [90]. The severity of alcoholic" exact="hepatitis" post="is linked to EVs containing CD34+ and ASGPR+ [91]."/>
 <result pre="[91]. 4.3. Liquid Biopsies of Markers Associated with Inflammation in" exact="Alcoholic" post="Liver Disease (ALD) The accumulation of hepatic macrophages has"/>
 <result pre="4.3. Liquid Biopsies of Markers Associated with Inflammation in Alcoholic" exact="Liver Disease" post="(ALD) The accumulation of hepatic macrophages has been observed"/>
 <result pre="Liquid Biopsies of Markers Associated with Inflammation in Alcoholic Liver" exact="Disease" post="(ALD) The accumulation of hepatic macrophages has been observed"/>
 <result pre="that CD40L may stimulate the activation of macrophages in experimental" exact="alcoholic hepatitis" post="models [92]. Chemotaxis is the initiating step in neutrophil"/>
 <result pre="CD40L may stimulate the activation of macrophages in experimental alcoholic" exact="hepatitis" post="models [92]. Chemotaxis is the initiating step in neutrophil"/>
 <result pre="in both circulating and hepatic neutrophils, which are associated with" exact="alcoholic hepatitis" post="and disease aggression [94,95,96]. CXCL1 is an IL-8 homologue"/>
 <result pre="both circulating and hepatic neutrophils, which are associated with alcoholic" exact="hepatitis" post="and disease aggression [94,95,96]. CXCL1 is an IL-8 homologue"/>
 <result pre="and hepatic neutrophils, which are associated with alcoholic hepatitis and" exact="disease" post="aggression [94,95,96]. CXCL1 is an IL-8 homologue that has"/>
 <result pre="which facilitates the pro-angiogenic effects of endothelial-derived vesicles [98]. The" exact="alcoholic" post="hepatitis-related liquid biomarkers are listed in Table 3. 5."/>
 <result pre="EVs/EPs and exosomes for liquid biopsies for the diagnosis of" exact="chronic" post="liver diseases (Figure 4). Numerous studies have demonstrated that"/>
 <result pre="(Figure 4). Numerous studies have demonstrated that EVs affect the" exact="chronic" post="inflammatory response in the progression of liver diseases. EVs"/>
 <result pre="that EVs affect the chronic inflammatory response in the progression" exact="of liver" post="diseases. EVs released from stressed hepatocytes are fundamental modulators"/>
 <result pre="they are implicated in complex networks of cell-to-cell communication in" exact="liver disease" post="development and progression. Some studies have presented analyses of"/>
 <result pre="are implicated in complex networks of cell-to-cell communication in liver" exact="disease" post="development and progression. Some studies have presented analyses of"/>
 <result pre="non-invasive and accurate approach to the diagnosis and monitoring of" exact="chronic" post="liver disease. Acknowledgments The authors thank all authors for"/>
 <result pre="and accurate approach to the diagnosis and monitoring of chronic" exact="liver disease." post="Acknowledgments The authors thank all authors for their publications"/>
 <result pre="Cohort Research Center KMU-TC108B07, KMU-DK109002 (HCC cohort) and Center of" exact="Cancer" post="Research (KMU-TC108A04-0), Kaohsiung Medical University in Taiwan. This study"/>
 <result pre="decision to publish the results. Abbreviations ALT alanine transaminase AH" exact="alcoholic hepatitis" post="ALD alcoholic liver disease ASH alcoholic steatohepatitis cfDNA cell-free"/>
 <result pre="to publish the results. Abbreviations ALT alanine transaminase AH alcoholic" exact="hepatitis" post="ALD alcoholic liver disease ASH alcoholic steatohepatitis cfDNA cell-free"/>
 <result pre="the results. Abbreviations ALT alanine transaminase AH alcoholic hepatitis ALD" exact="alcoholic" post="liver disease ASH alcoholic steatohepatitis cfDNA cell-free DNA CCL2"/>
 <result pre="results. Abbreviations ALT alanine transaminase AH alcoholic hepatitis ALD alcoholic" exact="liver disease" post="ASH alcoholic steatohepatitis cfDNA cell-free DNA CCL2 chemokine (C-C"/>
 <result pre="Abbreviations ALT alanine transaminase AH alcoholic hepatitis ALD alcoholic liver" exact="disease" post="ASH alcoholic steatohepatitis cfDNA cell-free DNA CCL2 chemokine (C-C"/>
 <result pre="alanine transaminase AH alcoholic hepatitis ALD alcoholic liver disease ASH" exact="alcoholic" post="steatohepatitis cfDNA cell-free DNA CCL2 chemokine (C-C motif) ligand"/>
 <result pre="motif) ligand 2 CXCL1 chemokine (C-X-C motif) ligand 1 CHB" exact="chronic hepatitis" post="B virus CHC chronic hepatitis C virus cccDNA covalently"/>
 <result pre="ligand 2 CXCL1 chemokine (C-X-C motif) ligand 1 CHB chronic" exact="hepatitis" post="B virus CHC chronic hepatitis C virus cccDNA covalently"/>
 <result pre="(C-X-C motif) ligand 1 CHB chronic hepatitis B virus CHC" exact="chronic hepatitis" post="C virus cccDNA covalently closed circular DNA dsDNA double-stranded"/>
 <result pre="motif) ligand 1 CHB chronic hepatitis B virus CHC chronic" exact="hepatitis" post="C virus cccDNA covalently closed circular DNA dsDNA double-stranded"/>
 <result pre="DNA ESCRT endosomal sorting complexes required for transport EV extracellular" exact="vesicle" post="GWAS genome-wide association study HSC hepatic stellate cell HAV"/>
 <result pre="vesicle GWAS genome-wide association study HSC hepatic stellate cell HAV" exact="hepatitis" post="A virus HBV hepatitis B virus HCV hepatitis C"/>
 <result pre="study HSC hepatic stellate cell HAV hepatitis A virus HBV" exact="hepatitis" post="B virus HCV hepatitis C virus HGV hepatitis G"/>
 <result pre="cell HAV hepatitis A virus HBV hepatitis B virus HCV" exact="hepatitis" post="C virus HGV hepatitis G virus HCC hepatocellular carcinoma"/>
 <result pre="virus HBV hepatitis B virus HCV hepatitis C virus HGV" exact="hepatitis" post="G virus HCC hepatocellular carcinoma Hcy homocysteine HuH human"/>
 <result pre="virus HCV hepatitis C virus HGV hepatitis G virus HCC" exact="hepatocellular carcinoma" post="Hcy homocysteine HuH human hepatocyte-derived carcinoma cell ILV intraluminal"/>
 <result pre="HCV hepatitis C virus HGV hepatitis G virus HCC hepatocellular" exact="carcinoma" post="Hcy homocysteine HuH human hepatocyte-derived carcinoma cell ILV intraluminal"/>
 <result pre="G virus HCC hepatocellular carcinoma Hcy homocysteine HuH human hepatocyte-derived" exact="carcinoma" post="cell ILV intraluminal vesicle lncRNA long non-coding RNA LPC"/>
 <result pre="carcinoma Hcy homocysteine HuH human hepatocyte-derived carcinoma cell ILV intraluminal" exact="vesicle" post="lncRNA long non-coding RNA LPC lysophosphatidylcholine LPC lysophosphatidylcholine MSC"/>
 <result pre="MPs/MVs microparticles/microvesicles miRNA microRNA mtDNA mitochondrial DNA MVB multivesicular body" exact="NAFLD" post="non-alcoholic fatty liver disease NASH non-alcoholic steatohepatitis PA palmitic"/>
 <result pre="microparticles/microvesicles miRNA microRNA mtDNA mitochondrial DNA MVB multivesicular body NAFLD" exact="non-alcoholic fatty liver" post="disease NASH non-alcoholic steatohepatitis PA palmitic acid PBMC peripheral"/>
 <result pre="miRNA microRNA mtDNA mitochondrial DNA MVB multivesicular body NAFLD non-alcoholic" exact="fatty liver disease" post="NASH non-alcoholic steatohepatitis PA palmitic acid PBMC peripheral blood"/>
 <result pre="microRNA mtDNA mitochondrial DNA MVB multivesicular body NAFLD non-alcoholic fatty" exact="liver disease" post="NASH non-alcoholic steatohepatitis PA palmitic acid PBMC peripheral blood"/>
 <result pre="mtDNA mitochondrial DNA MVB multivesicular body NAFLD non-alcoholic fatty liver" exact="disease" post="NASH non-alcoholic steatohepatitis PA palmitic acid PBMC peripheral blood"/>
 <result pre="fatty liver disease NASH non-alcoholic steatohepatitis PA palmitic acid PBMC" exact="peripheral" post="blood mononuclear cell PPARγ peroxisome proliferator-activated receptor gamma pgRNA"/>
 <result pre="2 TLR9 toll-like receptor 9 TAG triacylglycerol TG triacylglycerol TNFRSF10B" exact="tumor" post="necrosis factor receptor superfamily member 10B VLDL very-low-density lipoprotein"/>
 <result pre="differentiation 81 CLDN-1 claudin 1 SR-B1 scavenger receptor class B" exact="type 1" post="OCLN occludin Ago2 argonaute RISC catalytic component 2 ACC"/>
 <result pre="catalytic component 2 ACC acetyl-CoA carboxylase ALKP alkaline phosphatase TNFα" exact="tumor" post="necrosis factor alpha Tsg101 tumor susceptibility 101 References References"/>
 <result pre="carboxylase ALKP alkaline phosphatase TNFα tumor necrosis factor alpha Tsg101" exact="tumor" post="susceptibility 101 References References 1.AsraniS.K.DevarbhaviH.EatonJ.KamathP.S.Burden of liver diseases in"/>
 <result pre="necrosis factor alpha Tsg101 tumor susceptibility 101 References References 1.AsraniS.K.DevarbhaviH.EatonJ.KamathP.S.Burden" exact="of liver" post="diseases in the worldJ. Hepatol.20197015117110.1016/j.jhep.2018.09.01430266282 2.PerumpailB.J.KhanM.A.YooE.R.CholankerilG.KimD.AhmedA.Clinical epidemiology and disease"/>
 <result pre="of liver diseases in the worldJ. Hepatol.20197015117110.1016/j.jhep.2018.09.01430266282 2.PerumpailB.J.KhanM.A.YooE.R.CholankerilG.KimD.AhmedA.Clinical epidemiology and" exact="disease" post="burden of nonalcoholic fatty liver diseaseWorld J. Gastroenterol.2017238263827610.3748/wjg.v23.i47.826329307986 3.HsuP.Y.HsuC.T.YehM.L.HuangC.F.HuangC.I.LiangP.C.LinY.H.HsiehM.Y.WeiY.J.HsiehM.H.et"/>
 <result pre="the worldJ. Hepatol.20197015117110.1016/j.jhep.2018.09.01430266282 2.PerumpailB.J.KhanM.A.YooE.R.CholankerilG.KimD.AhmedA.Clinical epidemiology and disease burden of nonalcoholic" exact="fatty liver" post="diseaseWorld J. Gastroenterol.2017238263827610.3748/wjg.v23.i47.826329307986 3.HsuP.Y.HsuC.T.YehM.L.HuangC.F.HuangC.I.LiangP.C.LinY.H.HsiehM.Y.WeiY.J.HsiehM.H.et al.Early fibrosis but late tumor"/>
 <result pre="fatty liver diseaseWorld J. Gastroenterol.2017238263827610.3748/wjg.v23.i47.826329307986 3.HsuP.Y.HsuC.T.YehM.L.HuangC.F.HuangC.I.LiangP.C.LinY.H.HsiehM.Y.WeiY.J.HsiehM.H.et al.Early fibrosis but late" exact="tumor" post="stage and worse outcomes in hepatocellular carcinoma patients without"/>
 <result pre="al.Early fibrosis but late tumor stage and worse outcomes in" exact="hepatocellular carcinoma" post="patients without hepatitis B or hepatitis CDig. Dis. Sci.201910.1007/s10620-019-05938-331722058"/>
 <result pre="fibrosis but late tumor stage and worse outcomes in hepatocellular" exact="carcinoma" post="patients without hepatitis B or hepatitis CDig. Dis. Sci.201910.1007/s10620-019-05938-331722058"/>
 <result pre="tumor stage and worse outcomes in hepatocellular carcinoma patients without" exact="hepatitis" post="B or hepatitis CDig. Dis. Sci.201910.1007/s10620-019-05938-331722058 4.JunT.W.YehM.L.YangJ.D.ChenV.L.NguyenP.GiamaN.H.HuangC.F.HsingA.W.DaiC.Y.HuangJ.F.et al.More advanced"/>
 <result pre="worse outcomes in hepatocellular carcinoma patients without hepatitis B or" exact="hepatitis" post="CDig. Dis. Sci.201910.1007/s10620-019-05938-331722058 4.JunT.W.YehM.L.YangJ.D.ChenV.L.NguyenP.GiamaN.H.HuangC.F.HsingA.W.DaiC.Y.HuangJ.F.et al.More advanced disease and worse"/>
 <result pre="hepatitis B or hepatitis CDig. Dis. Sci.201910.1007/s10620-019-05938-331722058 4.JunT.W.YehM.L.YangJ.D.ChenV.L.NguyenP.GiamaN.H.HuangC.F.HsingA.W.DaiC.Y.HuangJ.F.et al.More advanced" exact="disease" post="and worse survival in cryptogenic compared to viral hepatocellular"/>
 <result pre="al.More advanced disease and worse survival in cryptogenic compared to" exact="viral" post="hepatocellular carcinomaLiver Int.20183889590210.1111/liv.1361329045023 5.LindenmeyerC.C.McCulloughA.J.The natural history of nonalcoholic fatty"/>
 <result pre="to viral hepatocellular carcinomaLiver Int.20183889590210.1111/liv.1361329045023 5.LindenmeyerC.C.McCulloughA.J.The natural history of nonalcoholic" exact="fatty liver" post="disease-an evolving viewClin. Liver. Dis.201822112110.1016/j.cld.2017.08.00329128051 6.HorowitzJ.M.VenkateshS.K.EhmanR.L.JhaveriK.KamathP.OhligerM.A.SamirA.E.SilvaA.C.TaouliB.TorbensonM.S.et al.Evaluation of hepatic"/>
 <result pre="hepatic fibrosis: A review from the society of abdominal radiology" exact="disease" post="focus panelAbdom. Radiol. (NY)2017422037205310.1007/s00261-017-1211-728624924 7.RatnerM.Jury out on liquid biopsies"/>
 <result pre="on liquid biopsies for cancerNat. Biotechnol.20183620921010.1038/nbt0318-209a 8.KonoshenkoM.Y.LekchnovE.A.VlassovA.V.LaktionovP.P.Isolation of extracellular vesicles:" exact="General" post="methodologies and latest trendsBiomed. Res. Int.2018854534710.1155/2018/854534729662902 9.CocucciE.MeldolesiJ.Ectosomes and exosomes:"/>
 <result pre="comparison defines novel markers to characterize heterogeneous populations of extracellular" exact="vesicle" post="subtypesProc. Natl. Acad. Sci. USA2016113E968E97710.1073/pnas.152123011326858453 11.BarileL.VassalliG.Exosomes: Therapy delivery tools"/>
 <result pre="an envelope by hijacking cellular membranesNature201349636737110.1038/nature1202923542590 22.McKnightK.L.XieL.Gonzalez-LopezO.Rivera-SerranoE.E.ChenX.LemonS.M.Protein composition of the" exact="hepatitis" post="A virus quasi-envelopeProc. Natl. Acad. Sci. USA20171146587659210.1073/pnas.161951911428490497 23.NagashimaS.JirintaiS.TakahashiM.KobayashiT.TanggisNishizawaT.KoukiT.YashiroT.OkamotoH.Hepatitis E"/>
 <result pre="from multivesicular bodiesJ. Gen. Virol.2014952166217510.1099/vir.0.066910-024970738 24.LindenbachB.D.RiceC.M.The ins and outs of" exact="hepatitis" post="C virus entry and assemblyNat. Rev. Microbiol.20131168870010.1038/nrmicro309824018384 25.BukongT.N.Momen-HeraviF.KodysK.BalaS.SzaboG.Exosomes from"/>
 <result pre="hepatitis C virus entry and assemblyNat. Rev. Microbiol.20131168870010.1038/nrmicro309824018384 25.BukongT.N.Momen-HeraviF.KodysK.BalaS.SzaboG.Exosomes from" exact="hepatitis" post="C infected patients transmit HCV infection and contain replication"/>
 <result pre="Rev. Microbiol.20131168870010.1038/nrmicro309824018384 25.BukongT.N.Momen-HeraviF.KodysK.BalaS.SzaboG.Exosomes from hepatitis C infected patients transmit HCV" exact="infection" post="and contain replication competent viral RNA in complex with"/>
 <result pre="C infected patients transmit HCV infection and contain replication competent" exact="viral" post="RNA in complex with Ago2-miR122-HSP90PLoS Pathog.201410e100442410.1371/journal.ppat.100442425275643 26.MeulemanP.HesselgesserJ.PaulsonM.VanwolleghemT.DesombereI.ReiserH.Leroux-RoelsG.Anti-CD81 antibodies can"/>
 <result pre="in complex with Ago2-miR122-HSP90PLoS Pathog.201410e100442410.1371/journal.ppat.100442425275643 26.MeulemanP.HesselgesserJ.PaulsonM.VanwolleghemT.DesombereI.ReiserH.Leroux-RoelsG.Anti-CD81 antibodies can prevent a" exact="hepatitis" post="C virus infection in vivoHepatology2008481761176810.1002/hep.2254719030166 27.HarmanA.N.NasrN.FeethamA.GaloyanA.AlshehriA.A.RambukwelleD.BottingR.A.HienerB.M.DiefenbachE.DiefenbachR.J.et al.HIV blocks interferon"/>
 <result pre="with Ago2-miR122-HSP90PLoS Pathog.201410e100442410.1371/journal.ppat.100442425275643 26.MeulemanP.HesselgesserJ.PaulsonM.VanwolleghemT.DesombereI.ReiserH.Leroux-RoelsG.Anti-CD81 antibodies can prevent a hepatitis C" exact="virus infection" post="in vivoHepatology2008481761176810.1002/hep.2254719030166 27.HarmanA.N.NasrN.FeethamA.GaloyanA.AlshehriA.A.RambukwelleD.BottingR.A.HienerB.M.DiefenbachE.DiefenbachR.J.et al.HIV blocks interferon induction in human"/>
 <result pre="Ago2-miR122-HSP90PLoS Pathog.201410e100442410.1371/journal.ppat.100442425275643 26.MeulemanP.HesselgesserJ.PaulsonM.VanwolleghemT.DesombereI.ReiserH.Leroux-RoelsG.Anti-CD81 antibodies can prevent a hepatitis C virus" exact="infection" post="in vivoHepatology2008481761176810.1002/hep.2254719030166 27.HarmanA.N.NasrN.FeethamA.GaloyanA.AlshehriA.A.RambukwelleD.BottingR.A.HienerB.M.DiefenbachE.DiefenbachR.J.et al.HIV blocks interferon induction in human"/>
 <result pre="protein-mediated inhibition of TCR signalingJ. Immunol.20131906351635910.4049/jimmunol.130058923686495 29.collab: Global Burden of" exact="Disease" post="Liver Cancer CollaborationAkinyemijuT.AberaS.AhmedM.AlamN.AlemayohuM.A.AllenC.Al-RaddadiR.Alvis-GuzmanN.AmoakoY.et al.The burden of primary liver cancer"/>
 <result pre="of TCR signalingJ. Immunol.20131906351635910.4049/jimmunol.130058923686495 29.collab: Global Burden of Disease Liver" exact="Cancer" post="CollaborationAkinyemijuT.AberaS.AhmedM.AlamN.AlemayohuM.A.AllenC.Al-RaddadiR.Alvis-GuzmanN.AmoakoY.et al.The burden of primary liver cancer and underlying"/>
 <result pre="Global Burden of Disease Liver Cancer CollaborationAkinyemijuT.AberaS.AhmedM.AlamN.AlemayohuM.A.AllenC.Al-RaddadiR.Alvis-GuzmanN.AmoakoY.et al.The burden of" exact="primary" post="liver cancer and underlying etiologies from 1990 to 2015"/>
 <result pre="Burden of Disease Liver Cancer CollaborationAkinyemijuT.AberaS.AhmedM.AlamN.AlemayohuM.A.AllenC.Al-RaddadiR.Alvis-GuzmanN.AmoakoY.et al.The burden of primary" exact="liver cancer" post="and underlying etiologies from 1990 to 2015 at the"/>
 <result pre="of Disease Liver Cancer CollaborationAkinyemijuT.AberaS.AhmedM.AlamN.AlemayohuM.A.AllenC.Al-RaddadiR.Alvis-GuzmanN.AmoakoY.et al.The burden of primary liver" exact="cancer" post="and underlying etiologies from 1990 to 2015 at the"/>
 <result pre="regional, and national level: Results from the Global Burden of" exact="Disease" post="Study 2015JAMA Oncol.201731683169110.1001/jamaoncol.2017.305528983565 30.SahaB.KodysK.SzaboG.Hepatitis C virus-induced monocyte differentiation into"/>
 <result pre="Global Burden of Disease Study 2015JAMA Oncol.201731683169110.1001/jamaoncol.2017.305528983565 30.SahaB.KodysK.SzaboG.Hepatitis C virus-induced" exact="monocyte" post="differentiation into polarized M2 macrophages promotes stellate cell activation"/>
 <result pre="via TGF-betaCell Mol. Gastroenterol. Hepatol.2016230231610.1016/j.jcmgh.2015.12.00528090562 31.FusegawaH.ShiraishiK.OgasawaraF.ShimizuM.HarukiY.MiyachiH.MatsuzakiS.AndoY.Platelet activation in patients with" exact="chronic hepatitis" post="CTokai J. Exp. Clin. Med.20022710110612713014 32.KornekM.LynchM.MehtaS.H.LaiM.ExleyM.AfdhalN.H.SchuppanD.Circulating microparticles as disease-specific"/>
 <result pre="TGF-betaCell Mol. Gastroenterol. Hepatol.2016230231610.1016/j.jcmgh.2015.12.00528090562 31.FusegawaH.ShiraishiK.OgasawaraF.ShimizuM.HarukiY.MiyachiH.MatsuzakiS.AndoY.Platelet activation in patients with chronic" exact="hepatitis" post="CTokai J. Exp. Clin. Med.20022710110612713014 32.KornekM.LynchM.MehtaS.H.LaiM.ExleyM.AfdhalN.H.SchuppanD.Circulating microparticles as disease-specific"/>
 <result pre="as disease-specific biomarkers of severity of inflammation in patients with" exact="hepatitis" post="C or nonalcoholic steatohepatitisGastroenterology201214344845810.1053/j.gastro.2012.04.03122537612 33.LiJ.LiuK.LiuY.XuY.ZhangF.YangH.LiuJ.PanT.ChenJ.WuM.et al.Exosomes mediate the cell-to-cell"/>
 <result pre="IFN-alpha-induced antiviral activityNat. Immunol.20131479380310.1038/ni.264723832071 34.RamakrishnaiahV.ThumannC.FofanaI.HabersetzerF.PanQ.de RuiterP.E.WillemsenR.DemmersJ.A.Stalin RajV.JensterG.et al.Exosome-mediated transmission of" exact="hepatitis" post="C virus between human hepatoma Huh7.5 cellsProc. Natl. Acad."/>
 <result pre="hepatoma Huh7.5 cellsProc. Natl. Acad. Sci. USA2013110131091311310.1073/pnas.122189911023878230 35.SzaboG.Momen-HeraviF.Extracellular vesicles in" exact="liver disease" post="and potential as biomarkers and therapeutic targetsNat. Rev. Gastroenterol."/>
 <result pre="Huh7.5 cellsProc. Natl. Acad. Sci. USA2013110131091311310.1073/pnas.122189911023878230 35.SzaboG.Momen-HeraviF.Extracellular vesicles in liver" exact="disease" post="and potential as biomarkers and therapeutic targetsNat. Rev. Gastroenterol."/>
 <result pre="Med.20185647948410.1515/cclm-2017-032729252188 37.RuanL.HuangL.ZhaoL.WangQ.PanX.ZhangA.BaiQ.LvZ.The Interaction of lncRNA-HEIH and lncRNA-HULC with HBXIP in" exact="hepatitis" post="B patientsGastroenterol. Res. Pract.20182018918731610.1155/2018/918731630622563 38.LiuY.FengJ.SunM.YangG.YuanH.WangY.BuY.ZhaoM.ZhangS.ZhangX.Long non-coding RNA HULC activates"/>
 <result pre="the MICA promoter which regulates MICA expression and increases HCV-related" exact="hepatocellular carcinoma" post="riskPLoS ONE20138e6127910.1371/journal.pone.006127923593449 41.HuangC.F.WangS.C.YehM.L.HuangC.I.TsaiP.C.LinZ.Y.ChenS.C.DaiC.Y.HuangJ.F.ChuangW.L.et al.Association of serial serum major histocompatibility"/>
 <result pre="MICA promoter which regulates MICA expression and increases HCV-related hepatocellular" exact="carcinoma" post="riskPLoS ONE20138e6127910.1371/journal.pone.006127923593449 41.HuangC.F.WangS.C.YehM.L.HuangC.I.TsaiP.C.LinZ.Y.ChenS.C.DaiC.Y.HuangJ.F.ChuangW.L.et al.Association of serial serum major histocompatibility"/>
 <result pre="serum major histocompatibility complex class I chain-related A measurements with" exact="hepatocellular carcinoma" post="in chronic hepatitis C patients after viral eradicationJ. Gastroenterol."/>
 <result pre="major histocompatibility complex class I chain-related A measurements with hepatocellular" exact="carcinoma" post="in chronic hepatitis C patients after viral eradicationJ. Gastroenterol."/>
 <result pre="complex class I chain-related A measurements with hepatocellular carcinoma in" exact="chronic hepatitis" post="C patients after viral eradicationJ. Gastroenterol. Hepatol.20193424925510.1111/jgh.1435929932235 42.HuangC.F.WangS.C.ChangW.T.YehM.L.HuangC.I.LinZ.Y.ChenS.C.ChuangW.L.HuangJ.F.DaiC.Y.et al.Lower"/>
 <result pre="class I chain-related A measurements with hepatocellular carcinoma in chronic" exact="hepatitis" post="C patients after viral eradicationJ. Gastroenterol. Hepatol.20193424925510.1111/jgh.1435929932235 42.HuangC.F.WangS.C.ChangW.T.YehM.L.HuangC.I.LinZ.Y.ChenS.C.ChuangW.L.HuangJ.F.DaiC.Y.et al.Lower"/>
 <result pre="measurements with hepatocellular carcinoma in chronic hepatitis C patients after" exact="viral" post="eradicationJ. Gastroenterol. Hepatol.20193424925510.1111/jgh.1435929932235 42.HuangC.F.WangS.C.ChangW.T.YehM.L.HuangC.I.LinZ.Y.ChenS.C.ChuangW.L.HuangJ.F.DaiC.Y.et al.Lower protein expression levels of"/>
 <result pre="expression levels of MHC class I chain-related gene A in" exact="hepatocellular carcinoma" post="are at high risk of recurrence after surgical resectionSci."/>
 <result pre="levels of MHC class I chain-related gene A in hepatocellular" exact="carcinoma" post="are at high risk of recurrence after surgical resectionSci."/>
 <result pre="46.TokuhisaY.IizukaN.SakaidaI.MoribeT.FujitaN.MiuraT.TamatsukuriS.IshitsukaH.UchidaK.TeraiS.et al.Circulating cell-free DNA as a predictive marker for distant" exact="metastasis" post="of hepatitis C virus-related hepatocellular carcinomaBr. J. Cancer2007971399140310.1038/sj.bjc.660403417940509 47.IidaM.IizukaN.SakaidaI.MoribeT.FujitaN.MiuraT.TamatsukuriS.IshitsukaH.UchidaK.TeraiS.et"/>
 <result pre="cell-free DNA as a predictive marker for distant metastasis of" exact="hepatitis" post="C virus-related hepatocellular carcinomaBr. J. Cancer2007971399140310.1038/sj.bjc.660403417940509 47.IidaM.IizukaN.SakaidaI.MoribeT.FujitaN.MiuraT.TamatsukuriS.IshitsukaH.UchidaK.TeraiS.et al.Relation between"/>
 <result pre="between serum levels of cell-free DNA and inflammation status in" exact="hepatitis" post="C virus-related hepatocellular carcinomaOncol. Rep.20082076176518813815 48.NgC.K.Y.Di CostanzoG.G.TerraccianoL.M.PiscuoglioS.Circulating cell-free DNA"/>
 <result pre="Current insights and outlookFront. Med. (Lausanne)201857810.3389/fmed.2018.0007829632864 49.BrumbaughD.E.FriedmanJ.E.Developmental origins of nonalcoholic" exact="fatty liver" post="diseasePediatr. Res.20147514014710.1038/pr.2013.19324192698 50.PierantonelliI.Svegliati-BaroniG.Nonalcoholic fatty liver disease: Basic pathogenetic mechanisms"/>
 <result pre="(Lausanne)201857810.3389/fmed.2018.0007829632864 49.BrumbaughD.E.FriedmanJ.E.Developmental origins of nonalcoholic fatty liver diseasePediatr. Res.20147514014710.1038/pr.2013.19324192698 50.PierantonelliI.Svegliati-BaroniG.Nonalcoholic" exact="fatty liver" post="disease: Basic pathogenetic mechanisms in the progression from NAFLD"/>
 <result pre="fatty liver disease: Basic pathogenetic mechanisms in the progression from" exact="NAFLD" post="to NASHTransplantation2019103e1e1310.1097/TP.000000000000248030300287 51.ChanS.L.WongA.M.LeeK.WongN.ChanA.K.Personalized therapy for hepatocellular carcinoma: Where are"/>
 <result pre="Treat. Rev.201645778610.1016/j.ctrv.2016.02.00826995632 52.YangR.X.HuC.X.SunW.L.PanQ.ShenF.YangZ.SuQ.XuG.W.FanJ.G.Serum monounsaturated triacylglycerol predicts steatohepatitis in patients with" exact="non-alcoholic fatty liver" post="disease and chronic hepatitis BSci. Rep.201771051710.1038/s41598-017-11278-x28874844 53.FartouxL.ChazouillèresO.WendumD.PouponR.SerfatyL.Impact of steatosis"/>
 <result pre="Rev.201645778610.1016/j.ctrv.2016.02.00826995632 52.YangR.X.HuC.X.SunW.L.PanQ.ShenF.YangZ.SuQ.XuG.W.FanJ.G.Serum monounsaturated triacylglycerol predicts steatohepatitis in patients with non-alcoholic" exact="fatty liver disease" post="and chronic hepatitis BSci. Rep.201771051710.1038/s41598-017-11278-x28874844 53.FartouxL.ChazouillèresO.WendumD.PouponR.SerfatyL.Impact of steatosis on"/>
 <result pre="52.YangR.X.HuC.X.SunW.L.PanQ.ShenF.YangZ.SuQ.XuG.W.FanJ.G.Serum monounsaturated triacylglycerol predicts steatohepatitis in patients with non-alcoholic fatty" exact="liver disease" post="and chronic hepatitis BSci. Rep.201771051710.1038/s41598-017-11278-x28874844 53.FartouxL.ChazouillèresO.WendumD.PouponR.SerfatyL.Impact of steatosis on"/>
 <result pre="monounsaturated triacylglycerol predicts steatohepatitis in patients with non-alcoholic fatty liver" exact="disease" post="and chronic hepatitis BSci. Rep.201771051710.1038/s41598-017-11278-x28874844 53.FartouxL.ChazouillèresO.WendumD.PouponR.SerfatyL.Impact of steatosis on"/>
 <result pre="predicts steatohepatitis in patients with non-alcoholic fatty liver disease and" exact="chronic hepatitis" post="BSci. Rep.201771051710.1038/s41598-017-11278-x28874844 53.FartouxL.ChazouillèresO.WendumD.PouponR.SerfatyL.Impact of steatosis on progression of fibrosis"/>
 <result pre="steatohepatitis in patients with non-alcoholic fatty liver disease and chronic" exact="hepatitis" post="BSci. Rep.201771051710.1038/s41598-017-11278-x28874844 53.FartouxL.ChazouillèresO.WendumD.PouponR.SerfatyL.Impact of steatosis on progression of fibrosis"/>
 <result pre="of steatosis on progression of fibrosis in patients with mild" exact="hepatitis" post="CHepatology200541828710.1002/hep.2051915690484 54.MehtaS.R.ThomasE.L.BellJ.D.JohnstonD.G.Taylor-RobinsonS.D.Non-invasive means of measuring hepatic fat contentWorld J."/>
 <result pre="Gastroenterol.2008143476348310.3748/wjg.14.347618567074 55.HardyT.ZeybelM.DayC.P.DipperC.MassonS.McPhersonS.HendersonE.TiniakosD.WhiteS.FrenchJ.et al.Plasma DNA methylation: A potential biomarker for stratification" exact="of liver" post="fibrosis in non-alcoholic fatty liver diseaseGut2017661321132810.1136/gutjnl-2016-31152627002005 56.De CarvalhoS.C.MunizM.T.SiqueiraM.D.SiqueiraE.R.GomesA.V.SilvaK.A.BezerraL.C.D’AlmeidaV.de OliveiraC.P.PereiraL.M.Plasmatic"/>
 <result pre="55.HardyT.ZeybelM.DayC.P.DipperC.MassonS.McPhersonS.HendersonE.TiniakosD.WhiteS.FrenchJ.et al.Plasma DNA methylation: A potential biomarker for stratification of" exact="liver fibrosis" post="in non-alcoholic fatty liver diseaseGut2017661321132810.1136/gutjnl-2016-31152627002005 56.De CarvalhoS.C.MunizM.T.SiqueiraM.D.SiqueiraE.R.GomesA.V.SilvaK.A.BezerraL.C.D’AlmeidaV.de OliveiraC.P.PereiraL.M.Plasmatic higher"/>
 <result pre="methylation: A potential biomarker for stratification of liver fibrosis in" exact="non-alcoholic fatty liver" post="diseaseGut2017661321132810.1136/gutjnl-2016-31152627002005 56.De CarvalhoS.C.MunizM.T.SiqueiraM.D.SiqueiraE.R.GomesA.V.SilvaK.A.BezerraL.C.D’AlmeidaV.de OliveiraC.P.PereiraL.M.Plasmatic higher levels of homocysteine in"/>
 <result pre="A potential biomarker for stratification of liver fibrosis in non-alcoholic" exact="fatty liver" post="diseaseGut2017661321132810.1136/gutjnl-2016-31152627002005 56.De CarvalhoS.C.MunizM.T.SiqueiraM.D.SiqueiraE.R.GomesA.V.SilvaK.A.BezerraL.C.D’AlmeidaV.de OliveiraC.P.PereiraL.M.Plasmatic higher levels of homocysteine in"/>
 <result pre="liver diseaseGut2017661321132810.1136/gutjnl-2016-31152627002005 56.De CarvalhoS.C.MunizM.T.SiqueiraM.D.SiqueiraE.R.GomesA.V.SilvaK.A.BezerraL.C.D’AlmeidaV.de OliveiraC.P.PereiraL.M.Plasmatic higher levels of homocysteine in" exact="non-alcoholic fatty liver" post="disease (NAFLD)Nutr. J.2013123710.1186/1475-2891-12-3723547829 57.GulsenM.YesilovaZ.BagciS.UygunA.OzcanA.ErcinC.N.ErdilA.SanisogluS.Y.CakirE.AtesY.et al.Elevated plasma homocysteine concentrations as"/>
 <result pre="diseaseGut2017661321132810.1136/gutjnl-2016-31152627002005 56.De CarvalhoS.C.MunizM.T.SiqueiraM.D.SiqueiraE.R.GomesA.V.SilvaK.A.BezerraL.C.D’AlmeidaV.de OliveiraC.P.PereiraL.M.Plasmatic higher levels of homocysteine in non-alcoholic" exact="fatty liver disease" post="(NAFLD)Nutr. J.2013123710.1186/1475-2891-12-3723547829 57.GulsenM.YesilovaZ.BagciS.UygunA.OzcanA.ErcinC.N.ErdilA.SanisogluS.Y.CakirE.AtesY.et al.Elevated plasma homocysteine concentrations as a"/>
 <result pre="56.De CarvalhoS.C.MunizM.T.SiqueiraM.D.SiqueiraE.R.GomesA.V.SilvaK.A.BezerraL.C.D’AlmeidaV.de OliveiraC.P.PereiraL.M.Plasmatic higher levels of homocysteine in non-alcoholic fatty" exact="liver disease" post="(NAFLD)Nutr. J.2013123710.1186/1475-2891-12-3723547829 57.GulsenM.YesilovaZ.BagciS.UygunA.OzcanA.ErcinC.N.ErdilA.SanisogluS.Y.CakirE.AtesY.et al.Elevated plasma homocysteine concentrations as a"/>
 <result pre="CarvalhoS.C.MunizM.T.SiqueiraM.D.SiqueiraE.R.GomesA.V.SilvaK.A.BezerraL.C.D’AlmeidaV.de OliveiraC.P.PereiraL.M.Plasmatic higher levels of homocysteine in non-alcoholic fatty liver" exact="disease" post="(NAFLD)Nutr. J.2013123710.1186/1475-2891-12-3723547829 57.GulsenM.YesilovaZ.BagciS.UygunA.OzcanA.ErcinC.N.ErdilA.SanisogluS.Y.CakirE.AtesY.et al.Elevated plasma homocysteine concentrations as a"/>
 <result pre="homocysteine concentrations as a predictor of steatohepatitis in patients with" exact="non-alcoholic fatty liver" post="diseaseJ. Gastroenterol. Hepatol.2005201448145510.1111/j.1440-1746.2005.03891.x16105135 58.ChangB.XuM.J.ZhouZ.CaiY.LiM.WangW.FengD.BertolaA.WangH.KunosG.et al.Short- or long-term high-fat diet"/>
 <result pre="concentrations as a predictor of steatohepatitis in patients with non-alcoholic" exact="fatty liver" post="diseaseJ. Gastroenterol. Hepatol.2005201448145510.1111/j.1440-1746.2005.03891.x16105135 58.ChangB.XuM.J.ZhouZ.CaiY.LiM.WangW.FengD.BertolaA.WangH.KunosG.et al.Short- or long-term high-fat diet"/>
 <result pre="Gastroenterol. Hepatol.2005201448145510.1111/j.1440-1746.2005.03891.x16105135 58.ChangB.XuM.J.ZhouZ.CaiY.LiM.WangW.FengD.BertolaA.WangH.KunosG.et al.Short- or long-term high-fat diet feeding plus" exact="acute" post="ethanol binge synergistically induce acute liver injury in mice:"/>
 <result pre="long-term high-fat diet feeding plus acute ethanol binge synergistically induce" exact="acute" post="liver injury in mice: An important role for CXCL1Hepatology2015621070108510.1002/hep.2792126033752"/>
 <result pre="liver and adipose tissue of mice with high fat diet-induced" exact="obesity" post="and nonalcoholic fatty liver diseaseEur. J. Gastroenterol. Hepatol.20082084385410.1097/MEG.0b013e3282f9b20318794597 61.YoshidaM.Novel"/>
 <result pre="tissue of mice with high fat diet-induced obesity and nonalcoholic" exact="fatty liver" post="diseaseEur. J. Gastroenterol. Hepatol.20082084385410.1097/MEG.0b013e3282f9b20318794597 61.YoshidaM.Novel role of NPC1L1 in"/>
 <result pre="liver microRNAs are potential biomarkers for liver injury in experimental" exact="fatty liver" post="diseasePLoS ONE20149e11365110.1371/journal.pone.011365125470250 65.HirsovaP.IbrahimS.H.KrishnanA.VermaV.K.BronkS.F.WerneburgN.W.CharltonM.R.ShahV.H.MalhiH.GoresG.J.Lipid-induced signaling causes release of inflammatory extracellular"/>
 <result pre="cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through" exact="tumor" post="necrosis factor-alpha productionJ. Biol. Chem.2012287401614017210.1074/jbc.M112.41701423066023 68.IbrahimS.H.GoresG.J.HirsovaP.KirbyM.MilesL.JaeschkeA.KohliR.Mixed lineage kinase 3"/>
 <result pre="IRE1alpha-dependent mannerJ. Lipid. Res.20165723324510.1194/jlr.M06341226621917 76.GagginiM.CarliF.RossoC.YounesR.D’AurizioR.BugianesiE.GastaldelliA.Altered Metabolic Profile and Adipocyte Insulin" exact="Resistance" post="Mark Severe Liver Fibrosis in Patients with Chronic Liver"/>
 <result pre="Lipid. Res.20165723324510.1194/jlr.M06341226621917 76.GagginiM.CarliF.RossoC.YounesR.D’AurizioR.BugianesiE.GastaldelliA.Altered Metabolic Profile and Adipocyte Insulin Resistance Mark" exact="Severe" post="Liver Fibrosis in Patients with Chronic Liver DiseaseInt. J."/>
 <result pre="Adipocyte Insulin Resistance Mark Severe Liver Fibrosis in Patients with" exact="Chronic" post="Liver DiseaseInt. J. Mol. Sci.201920633310.3390/ijms20246333 77.GaoB.BatallerR.Alcoholic liver disease: Pathogenesis"/>
 <result pre="77.GaoB.BatallerR.Alcoholic liver disease: Pathogenesis and new therapeutic targetsGastroenterology20111411572158510.1053/j.gastro.2011.09.00221920463 78.GaoB.TsukamotoH.Inflammation in" exact="alcoholic" post="and nonalcoholic fatty liver disease: Friend or foe?Gastroenterology20161501704170910.1053/j.gastro.2016.01.02526826669 79.MillsS.J.HarrisonS.A.Comparison"/>
 <result pre="Pathogenesis and new therapeutic targetsGastroenterology20111411572158510.1053/j.gastro.2011.09.00221920463 78.GaoB.TsukamotoH.Inflammation in alcoholic and nonalcoholic" exact="fatty liver" post="disease: Friend or foe?Gastroenterology20161501704170910.1053/j.gastro.2016.01.02526826669 79.MillsS.J.HarrisonS.A.Comparison of the natural history"/>
 <result pre="disease: Friend or foe?Gastroenterology20161501704170910.1053/j.gastro.2016.01.02526826669 79.MillsS.J.HarrisonS.A.Comparison of the natural history of" exact="alcoholic" post="and nonalcoholic fatty liver diseaseCurr. Gastroenterol. Rep.20057323610.1007/s11894-005-0063-415701296 80.TrinchetJ.C.GerhardtM.F.BalkauB.MunzC.PouponR.E.Serum bile"/>
 <result pre="foe?Gastroenterology20161501704170910.1053/j.gastro.2016.01.02526826669 79.MillsS.J.HarrisonS.A.Comparison of the natural history of alcoholic and nonalcoholic" exact="fatty liver" post="diseaseCurr. Gastroenterol. Rep.20057323610.1007/s11894-005-0063-415701296 80.TrinchetJ.C.GerhardtM.F.BalkauB.MunzC.PouponR.E.Serum bile acids and cholestasis in"/>
 <result pre="nonalcoholic fatty liver diseaseCurr. Gastroenterol. Rep.20057323610.1007/s11894-005-0063-415701296 80.TrinchetJ.C.GerhardtM.F.BalkauB.MunzC.PouponR.E.Serum bile acids and" exact="cholestasis" post="in alcoholic hepatitis. Relationship with usual liver tests and"/>
 <result pre="liver diseaseCurr. Gastroenterol. Rep.20057323610.1007/s11894-005-0063-415701296 80.TrinchetJ.C.GerhardtM.F.BalkauB.MunzC.PouponR.E.Serum bile acids and cholestasis in" exact="alcoholic hepatitis." post="Relationship with usual liver tests and histological featuresJ. Hepatol.19942123524010.1016/S0168-8278(05)80401-57989715"/>
 <result pre="in plasmaPLoS ONE201510e011911010.1371/journal.pone.011911025775014 82.XuM.J.CaiY.WangH.AltamiranoJ.ChangB.BertolaA.OdenaG.LuJ.TanakaN.MatsusueK.et al.Fat-specific protein 27/CIDEC promotes development of" exact="alcoholic" post="steatohepatitis in mice and humansGastroenterology201514910301041.e610.1053/j.gastro.2015.06.00926099526 83.Momen-HeraviF.SahaB.KodysK.CatalanoD.SatishchandranA.SzaboG.Increased number of circulating"/>
 <result pre="exosomes and their microRNA cargos are potential novel biomarkers in" exact="alcoholic" post="hepatitisJ. Tranl. Med.20151326110.1186/s12967-015-0623-926264599 84.ChoY.E.MezeyE.HardwickJ.P.SalemN.Jr.ClemensD.L.SongB.J.Increased ethanol-inducible cytochrome P450-2E1 and cytochrome"/>
 <result pre="P450 isoforms in exosomes of alcohol-exposed rodents and patients with" exact="alcoholism" post="through oxidative and endoplasmic reticulum stressHepatol. Commun.2017167569010.1002/hep4.106629404485 85.BodeC.KuglerV.BodeJ.C.Endotoxemia in"/>
 <result pre="oxidative and endoplasmic reticulum stressHepatol. Commun.2017167569010.1002/hep4.106629404485 85.BodeC.KuglerV.BodeJ.C.Endotoxemia in patients with" exact="alcoholic" post="and non-alcoholic cirrhosis and in subjects with no evidence"/>
 <result pre="reticulum stressHepatol. Commun.2017167569010.1002/hep4.106629404485 85.BodeC.KuglerV.BodeJ.C.Endotoxemia in patients with alcoholic and non-alcoholic" exact="cirrhosis" post="and in subjects with no evidence of chronic liver"/>
 <result pre="and non-alcoholic cirrhosis and in subjects with no evidence of" exact="chronic" post="liver disease following acute alcohol excessJ. Hepatol.1987481410.1016/S0168-8278(87)80003-X3571935 86.CaiY.XuM.J.KoritzinskyE.H.ZhouZ.WangW.CaoH.YuenP.S.RossR.A.StarR.A.LiangpunsakulS.et al.Mitochondrial"/>
 <result pre="non-alcoholic cirrhosis and in subjects with no evidence of chronic" exact="liver disease" post="following acute alcohol excessJ. Hepatol.1987481410.1016/S0168-8278(87)80003-X3571935 86.CaiY.XuM.J.KoritzinskyE.H.ZhouZ.WangW.CaoH.YuenP.S.RossR.A.StarR.A.LiangpunsakulS.et al.Mitochondrial DNA-enriched microparticles"/>
 <result pre="cirrhosis and in subjects with no evidence of chronic liver" exact="disease" post="following acute alcohol excessJ. Hepatol.1987481410.1016/S0168-8278(87)80003-X3571935 86.CaiY.XuM.J.KoritzinskyE.H.ZhouZ.WangW.CaoH.YuenP.S.RossR.A.StarR.A.LiangpunsakulS.et al.Mitochondrial DNA-enriched microparticles"/>
 <result pre="in subjects with no evidence of chronic liver disease following" exact="acute" post="alcohol excessJ. Hepatol.1987481410.1016/S0168-8278(87)80003-X3571935 86.CaiY.XuM.J.KoritzinskyE.H.ZhouZ.WangW.CaoH.YuenP.S.RossR.A.StarR.A.LiangpunsakulS.et al.Mitochondrial DNA-enriched microparticles promote acute-on-chronic"/>
 <result pre="acute alcohol excessJ. Hepatol.1987481410.1016/S0168-8278(87)80003-X3571935 86.CaiY.XuM.J.KoritzinskyE.H.ZhouZ.WangW.CaoH.YuenP.S.RossR.A.StarR.A.LiangpunsakulS.et al.Mitochondrial DNA-enriched microparticles promote acute-on-chronic" exact="alcoholic" post="neutrophilia and hepatotoxicityJCI Insight201729263410.1172/jci.insight.9263428724791 87.SahaB.Momen-HeraviF.FuriI.KodysK.CatalanoD.GangopadhyayA.HarasztiR.SatishchandranA.Iracheta-VellveA.AdejumoA.et al.Extracellular vesicles from mice"/>
 <result pre="neutrophilia and hepatotoxicityJCI Insight201729263410.1172/jci.insight.9263428724791 87.SahaB.Momen-HeraviF.FuriI.KodysK.CatalanoD.GangopadhyayA.HarasztiR.SatishchandranA.Iracheta-VellveA.AdejumoA.et al.Extracellular vesicles from mice with" exact="alcoholic" post="liver disease carry a distinct protein cargo and induce"/>
 <result pre="and hepatotoxicityJCI Insight201729263410.1172/jci.insight.9263428724791 87.SahaB.Momen-HeraviF.FuriI.KodysK.CatalanoD.GangopadhyayA.HarasztiR.SatishchandranA.Iracheta-VellveA.AdejumoA.et al.Extracellular vesicles from mice with alcoholic" exact="liver disease" post="carry a distinct protein cargo and induce macrophage activation"/>
 <result pre="hepatotoxicityJCI Insight201729263410.1172/jci.insight.9263428724791 87.SahaB.Momen-HeraviF.FuriI.KodysK.CatalanoD.GangopadhyayA.HarasztiR.SatishchandranA.Iracheta-VellveA.AdejumoA.et al.Extracellular vesicles from mice with alcoholic liver" exact="disease" post="carry a distinct protein cargo and induce macrophage activation"/>
 <result pre="prospective study of the utility of plasma biomarkers to diagnose" exact="alcoholic" post="hepatitisHepatology20176655556310.1002/hep.2908028120471 91.SukritiS.MarasJ.S.BihariC.DasS.VyasA.K.SharmaS.HussainS.ShasthryS.ChoudharyA.PremkumarM.et al.Microvesicles in hepatic and peripheral vein can"/>
 <result pre="biomarkers to diagnose alcoholic hepatitisHepatology20176655556310.1002/hep.2908028120471 91.SukritiS.MarasJ.S.BihariC.DasS.VyasA.K.SharmaS.HussainS.ShasthryS.ChoudharyA.PremkumarM.et al.Microvesicles in hepatic and" exact="peripheral" post="vein can predict nonresponse to corticosteroid therapy in severe"/>
 <result pre="peripheral vein can predict nonresponse to corticosteroid therapy in severe" exact="alcoholic" post="hepatitisAliment Pharmacol. Ther.2018471151116110.1111/apt.1456429460445 92.VermaV.K.LiH.WangR.HirsovaP.MushrefM.LiuY.CaoS.ContrerasP.C.MalhiH.KamathP.S.et al.Alcohol stimulates macrophage activation through"/>
 <result pre="role of chemokines in neutrophil biologyFront. Biosci.2008132400240710.2741/285317981721 94.BautistaA.P.Neutrophilic infiltration in" exact="alcoholic" post="hepatitisAlcohol200227172110.1016/S0741-8329(02)00206-912062632 95.DominguezM.MiquelR.ColmeneroJ.MorenoM.García-PagánJ.C.BoschJ.ArroyoV.GinèsP.CaballeríaJ.BatallerR.Hepatic expression of CXC chemokines predicts portal hypertension"/>
 <result pre="infiltration in alcoholic hepatitisAlcohol200227172110.1016/S0741-8329(02)00206-912062632 95.DominguezM.MiquelR.ColmeneroJ.MorenoM.García-PagánJ.C.BoschJ.ArroyoV.GinèsP.CaballeríaJ.BatallerR.Hepatic expression of CXC chemokines predicts" exact="portal hypertension" post="and survival in patients with alcoholic hepatitisGastroenterology20091361639165010.1053/j.gastro.2009.01.05619208360 96.SheronN.BirdG.KoskinasJ.PortmannB.CeskaM.LindleyI.WilliamsR.Circulating and"/>
 <result pre="in alcoholic hepatitisAlcohol200227172110.1016/S0741-8329(02)00206-912062632 95.DominguezM.MiquelR.ColmeneroJ.MorenoM.García-PagánJ.C.BoschJ.ArroyoV.GinèsP.CaballeríaJ.BatallerR.Hepatic expression of CXC chemokines predicts portal" exact="hypertension" post="and survival in patients with alcoholic hepatitisGastroenterology20091361639165010.1053/j.gastro.2009.01.05619208360 96.SheronN.BirdG.KoskinasJ.PortmannB.CeskaM.LindleyI.WilliamsR.Circulating and"/>
 <result pre="CXC chemokines predicts portal hypertension and survival in patients with" exact="alcoholic" post="hepatitisGastroenterology20091361639165010.1053/j.gastro.2009.01.05619208360 96.SheronN.BirdG.KoskinasJ.PortmannB.CeskaM.LindleyI.WilliamsR.Circulating and tissue levels of the neutrophil chemotaxin"/>
 <result pre="levels of the neutrophil chemotaxin interleukin-8 are elevated in severe" exact="acute" post="alcoholic hepatitis, and tissue levels correlate with neutrophil infiltrationHepatology19931841468325620"/>
 <result pre="of the neutrophil chemotaxin interleukin-8 are elevated in severe acute" exact="alcoholic hepatitis," post="and tissue levels correlate with neutrophil infiltrationHepatology19931841468325620 97.RohY.S.ZhangB.LoombaR.SekiE.TLR2 and"/>
 <result pre="and long non-coding RNAsSci. Rep.201771379410.1038/s41598-017-14356-229062004 Figure 1 Summary of the" exact="viral" post="liquid biopsy markers driven by hepatitis viruses in the"/>
 <result pre="1 Summary of the viral liquid biopsy markers driven by" exact="hepatitis" post="viruses in the pathogenesis of viral hepatitis. Classification of"/>
 <result pre="biopsy markers driven by hepatitis viruses in the pathogenesis of" exact="viral hepatitis." post="Classification of viral related liquid biopsies by viral infection"/>
 <result pre="hepatitis viruses in the pathogenesis of viral hepatitis. Classification of" exact="viral" post="related liquid biopsies by viral infection and transmission, viral"/>
 <result pre="of viral hepatitis. Classification of viral related liquid biopsies by" exact="viral infection" post="and transmission, viral replication, and viral invasion on the"/>
 <result pre="viral hepatitis. Classification of viral related liquid biopsies by viral" exact="infection" post="and transmission, viral replication, and viral invasion on the"/>
 <result pre="of viral related liquid biopsies by viral infection and transmission," exact="viral" post="replication, and viral invasion on the HAV (◼), HBV(◼),"/>
 <result pre="liquid biopsies by viral infection and transmission, viral replication, and" exact="viral" post="invasion on the HAV (◼), HBV(◼), HCV(◼), HEV(▮), and"/>
 <result pre="in ceramide (C16:0)-derived sphingosine 1 phosphate (S1P) to chemoattract macrophages." exact="Increased" post="numbers of EVs derived from invariant natural killer T"/>
 <result pre="Figure 3 The summary of the liquid factors associated with" exact="liver inflammation" post="in Alcoholic liver disease (ALD). Figure 4 The potential"/>
 <result pre="summary of the liquid factors associated with liver inflammation in" exact="Alcoholic" post="liver disease (ALD). Figure 4 The potential of the"/>
 <result pre="of the liquid factors associated with liver inflammation in Alcoholic" exact="liver disease" post="(ALD). Figure 4 The potential of the liquid biopsy"/>
 <result pre="the liquid factors associated with liver inflammation in Alcoholic liver" exact="disease" post="(ALD). Figure 4 The potential of the liquid biopsy"/>
 <result pre="non-invasive and accurate approach to the diagnosis and monitoring of" exact="chronic" post="liver disease by disease associated markers from EVs, cfDNA,"/>
 <result pre="and accurate approach to the diagnosis and monitoring of chronic" exact="liver disease" post="by disease associated markers from EVs, cfDNA, and serum"/>
 <result pre="accurate approach to the diagnosis and monitoring of chronic liver" exact="disease" post="by disease associated markers from EVs, cfDNA, and serum"/>
 <result pre="to the diagnosis and monitoring of chronic liver disease by" exact="disease" post="associated markers from EVs, cfDNA, and serum protein. Biomarks"/>
 <result pre="The biomarks expression testing level not only to monitor the" exact="disease" post="process, also can apply for the drug design, drug"/>
 <result pre="efficiency in the future. ijms-21-03732-t001_Table 1Table 1 Liquid biomarkers of" exact="viral hepatitis" post="liver diseases. References Biomarker Type of Liquid Biopsy Application"/>
 <result pre="in the future. ijms-21-03732-t001_Table 1Table 1 Liquid biomarkers of viral" exact="hepatitis" post="liver diseases. References Biomarker Type of Liquid Biopsy Application"/>
 <result pre="hepatitis liver diseases. References Biomarker Type of Liquid Biopsy Application" exact="Disease" post="Source Sample Type McKnight, Xie et al. [22] MVB"/>
 <result pre="Source Sample Type McKnight, Xie et al. [22] MVB Exosomes" exact="Viral infection" post="HAV Infected cells Serum J Gen Virol 2014, Nagashima"/>
 <result pre="Sample Type McKnight, Xie et al. [22] MVB Exosomes Viral" exact="infection" post="HAV Infected cells Serum J Gen Virol 2014, Nagashima"/>
 <result pre="Gen Virol 2014, Nagashima S. et al. [23] MVB Exosomes" exact="Viral infection" post="HEV Infected cells Cell supernatants PLoS Pathog 2014, Bukong"/>
 <result pre="Virol 2014, Nagashima S. et al. [23] MVB Exosomes Viral" exact="infection" post="HEV Infected cells Cell supernatants PLoS Pathog 2014, Bukong"/>
 <result pre="Bukong TN. et al. [25] HSP90, Ago2, and mir-122 Exosomes" exact="Viral infection" post="HCV Infected cells Serum/Cell supernatants Clin Chem Lab Med."/>
 <result pre="TN. et al. [25] HSP90, Ago2, and mir-122 Exosomes Viral" exact="infection" post="HCV Infected cells Serum/Cell supernatants Clin Chem Lab Med."/>
 <result pre="[37] lncRNA-HEIH &amp;amp; lncRNA-HULC - Biomarker HBV Hepatocyte Peripheral blood" exact="Cancer" post="Biomark 2018, Zhang C. et al. [39] lncRNA-HEIH Exosomal"/>
 <result pre="J Gastroenterol Hepatol 2019, Huang CF. et al. [41] sMICA" exact="Protein" post="Biomarker HCV Infected cells Serum PLoS One. 2012, Kumar"/>
 <result pre="Hepatocyte Serum Viruses. 2017, Allweiss L. et al. [44] cccDNA" exact="Viral" post="DNA Diagnosis HBV Virus Serum/Cell supernatants Journal of Clinical"/>
 <result pre="of Clinical Microbiology 2019, Lin N. et al. [45] pgRNA" exact="Viral" post="RNA Diagnosis HBV Virus Serum Br J Cancer 2007,"/>
 <result pre="[45] pgRNA Viral RNA Diagnosis HBV Virus Serum Br J" exact="Cancer" post="2007, Tokuhisa Y. et al. [46] cfDNA HCC DNA"/>
 <result pre="Serum/plasma Gastroenterology 2012, Kornek M. et al. [32] Levels Microparticles" exact="Hepatic" post="inflammation HCV - Serum/plasma Multivesicular body (MVB); Cell-free DNA"/>
 <result pre="(MVB); Cell-free DNA (cfDNA); covalently closed circular DNA (cccDNA); extracellular" exact="vesicle" post="(EV); hepatitis A virus (HAV); hepatitis B virus (HBV);"/>
 <result pre="DNA (cfDNA); covalently closed circular DNA (cccDNA); extracellular vesicle (EV);" exact="hepatitis" post="A virus (HAV); hepatitis B virus (HBV); hepatitis C"/>
 <result pre="circular DNA (cccDNA); extracellular vesicle (EV); hepatitis A virus (HAV);" exact="hepatitis" post="B virus (HBV); hepatitis C virus (HCV); hepatitis G"/>
 <result pre="vesicle (EV); hepatitis A virus (HAV); hepatitis B virus (HBV);" exact="hepatitis" post="C virus (HCV); hepatitis G virus (HGV); human hepatocyte-derived"/>
 <result pre="virus (HAV); hepatitis B virus (HBV); hepatitis C virus (HCV);" exact="hepatitis" post="G virus (HGV); human hepatocyte-derived carcinoma cells (HuH); intraluminal"/>
 <result pre="hepatitis C virus (HCV); hepatitis G virus (HGV); human hepatocyte-derived" exact="carcinoma" post="cells (HuH); intraluminal vesicle (ILV); long non-coding RNA (lncRNA);"/>
 <result pre="hepatitis G virus (HGV); human hepatocyte-derived carcinoma cells (HuH); intraluminal" exact="vesicle" post="(ILV); long non-coding RNA (lncRNA); MHC class I chain-related"/>
 <result pre="(lncRNA); MHC class I chain-related A (MICA); multivesicular body (MVB);" exact="peripheral" post="blood mononuclear cell (PBMC); pre-genomic RNA (pgRNA); single nucleotide"/>
 <result pre="NASH diseases. References [ref] Biomarker Type of Liquid Biopsy Application" exact="Disease" post="Source Sample Type Hepatology. 2016, Ibrahim, S.H. et al."/>
 <result pre="ceramide and S1P EVs Diagnosis &amp;amp; monitoring biomarker NASH Hepatocytes" exact="Mouse" post="model Serum Gastroenterology 2012, Kornek M. et al. [32]"/>
 <result pre="Serum Gastroenterology 2012, Kornek M. et al. [32] Levels Microparticles" exact="Hepatic" post="inflammation NAFLD - Serum/plasma J Clin Invest 2016, Garcia-Martinez,"/>
 <result pre="2012, Kornek M. et al. [32] Levels Microparticles Hepatic inflammation" exact="NAFLD" post="- Serum/plasma J Clin Invest 2016, Garcia-Martinez, Santoro et"/>
 <result pre="Plasma Sci Rep. 2017, Yang RX. et al. [52] Triacylglycerol" exact="Protein" post="Diagnosis biomarker NAFLD - Serum J Gastroenterol Hepatol. 2005,"/>
 <result pre="2017, Yang RX. et al. [52] Triacylglycerol Protein Diagnosis biomarker" exact="NAFLD" post="- Serum J Gastroenterol Hepatol. 2005, Gulsen, M. et"/>
 <result pre="J Gastroenterol Hepatol. 2005, Gulsen, M. et al. [57] Hcy" exact="Protein" post="Predictor biomarkers NAFLD Hepatocytes plasma Gut. 2017, Hardy T."/>
 <result pre="2005, Gulsen, M. et al. [57] Hcy Protein Predictor biomarkers" exact="NAFLD" post="Hepatocytes plasma Gut. 2017, Hardy T. et al. [55]"/>
 <result pre="Hardy T. et al. [55] PPARγ DNA methylation Prognostic biomarker" exact="NAFLD" post="- Plasma Extracellular vesicles (EVs); cytochrome P450 2E1 (CYP2E1);"/>
 <result pre="Extracellular vesicles (EVs); cytochrome P450 2E1 (CYP2E1); mitochondrial DNA (mtDNA);" exact="non-alcoholic fatty liver" post="disease (NAFLD); non-alcoholic steatohepatitis (NASH); peroxisome proliferator-activated receptor gamma"/>
 <result pre="vesicles (EVs); cytochrome P450 2E1 (CYP2E1); mitochondrial DNA (mtDNA); non-alcoholic" exact="fatty liver disease" post="(NAFLD); non-alcoholic steatohepatitis (NASH); peroxisome proliferator-activated receptor gamma (PPARγ);"/>
 <result pre="(EVs); cytochrome P450 2E1 (CYP2E1); mitochondrial DNA (mtDNA); non-alcoholic fatty" exact="liver disease" post="(NAFLD); non-alcoholic steatohepatitis (NASH); peroxisome proliferator-activated receptor gamma (PPARγ);"/>
 <result pre="cytochrome P450 2E1 (CYP2E1); mitochondrial DNA (mtDNA); non-alcoholic fatty liver" exact="disease" post="(NAFLD); non-alcoholic steatohepatitis (NASH); peroxisome proliferator-activated receptor gamma (PPARγ);"/>
 <result pre="(S1P). homocysteine (Hcy); cytochrome P450 2E1 (CYP2E1); mitochondrial DNA (mtDNA);" exact="non-alcoholic fatty liver" post="disease (NAFLD); non-alcoholic steatohepatitis (NASH); peroxisome proliferator-activated receptor gamma"/>
 <result pre="homocysteine (Hcy); cytochrome P450 2E1 (CYP2E1); mitochondrial DNA (mtDNA); non-alcoholic" exact="fatty liver disease" post="(NAFLD); non-alcoholic steatohepatitis (NASH); peroxisome proliferator-activated receptor gamma (PPARγ);"/>
 <result pre="(Hcy); cytochrome P450 2E1 (CYP2E1); mitochondrial DNA (mtDNA); non-alcoholic fatty" exact="liver disease" post="(NAFLD); non-alcoholic steatohepatitis (NASH); peroxisome proliferator-activated receptor gamma (PPARγ);"/>
 <result pre="cytochrome P450 2E1 (CYP2E1); mitochondrial DNA (mtDNA); non-alcoholic fatty liver" exact="disease" post="(NAFLD); non-alcoholic steatohepatitis (NASH); peroxisome proliferator-activated receptor gamma (PPARγ);"/>
 <result pre="toll-like receptor 9 (TLR9). ijms-21-03732-t003_Table 3Table 3 Liquid biomarkers of" exact="alcoholic" post="liver diseases. References [ref] Biomarker Type of Liquid Biopsy"/>
 <result pre="liver diseases. References [ref] Biomarker Type of Liquid Biopsy Application" exact="Disease" post="Source Sample Type Hepatol 1994, [ref] Trinchet JC. et"/>
 <result pre="Hepatol 1994, [ref] Trinchet JC. et al. [80] Bile acids" exact="Protein" post="Diagnosis biomarker ASH - Serum PLoS One 2015, Moratti,"/>
 <result pre="Serum PLoS One 2015, Moratti, Vezzalini et al. [81] sPTPRG" exact="Protein" post="Prognosis biomarker AH - Plasma J Transl Med 2015,"/>
 <result pre="Momen-Heravi et al. [87] CCL2 EVs Prognosis biomarker AH -" exact="Mouse" post="model Serum PLoS One 2017, Cho, Im et al."/>
 <result pre="al. [98] lncRNA-HOTAIR lncRNA-MALAT1 EVs Prognosis biomarker AH Endothelial cells" exact="Mouse" post="model Serum Hepatology 2015, Chang, Xu et al. [58]"/>
 <result pre="et al. [58] CXCL1 - Prognosis biomarker ALD - Serum" exact="Protein" post="tyrosine phosphatase receptor gamma extracellular domain (sPTPRG); Alanine transaminase"/>
 <result pre="tyrosine phosphatase receptor gamma extracellular domain (sPTPRG); Alanine transaminase (ALT);" exact="alcoholic hepatitis" post="(AH); alcoholic liver disease (ALD); alcoholic steatohepatitis (ASH); chemokine"/>
 <result pre="phosphatase receptor gamma extracellular domain (sPTPRG); Alanine transaminase (ALT); alcoholic" exact="hepatitis" post="(AH); alcoholic liver disease (ALD); alcoholic steatohepatitis (ASH); chemokine"/>
 <result pre="gamma extracellular domain (sPTPRG); Alanine transaminase (ALT); alcoholic hepatitis (AH);" exact="alcoholic" post="liver disease (ALD); alcoholic steatohepatitis (ASH); chemokine (C-C motif)"/>
 <result pre="extracellular domain (sPTPRG); Alanine transaminase (ALT); alcoholic hepatitis (AH); alcoholic" exact="liver disease" post="(ALD); alcoholic steatohepatitis (ASH); chemokine (C-C motif) ligand 2"/>
 <result pre="domain (sPTPRG); Alanine transaminase (ALT); alcoholic hepatitis (AH); alcoholic liver" exact="disease" post="(ALD); alcoholic steatohepatitis (ASH); chemokine (C-C motif) ligand 2"/>
 <result pre="Alanine transaminase (ALT); alcoholic hepatitis (AH); alcoholic liver disease (ALD);" exact="alcoholic" post="steatohepatitis (ASH); chemokine (C-C motif) ligand 2 (CCL2); chemokine"/>
 <result pre="ligand 2 (CCL2); chemokine (C-X-C motif) ligand 1 (CXCL1); extracellular" exact="vesicle" post="(EV); Microvesicles (MVs); long non-coding RNA (lncRNA); microRNA (miR);"/>
</results>
